WO2009011591A2 - Novel arabinose-fermenting eukaryotic cells - Google Patents

Novel arabinose-fermenting eukaryotic cells Download PDF

Info

Publication number
WO2009011591A2
WO2009011591A2 PCT/NL2008/050500 NL2008050500W WO2009011591A2 WO 2009011591 A2 WO2009011591 A2 WO 2009011591A2 NL 2008050500 W NL2008050500 W NL 2008050500W WO 2009011591 A2 WO2009011591 A2 WO 2009011591A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
nucleotide sequence
arabinose
sequences
xylulose
Prior art date
Application number
PCT/NL2008/050500
Other languages
French (fr)
Other versions
WO2009011591A3 (en
Inventor
Johannes Adrianus Maria De Bont
Original Assignee
Royal Nedalco B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Nedalco B.V. filed Critical Royal Nedalco B.V.
Priority to CA2693365A priority Critical patent/CA2693365A1/en
Priority to EP08779046A priority patent/EP2171038A2/en
Priority to US12/669,688 priority patent/US20100304454A1/en
Publication of WO2009011591A2 publication Critical patent/WO2009011591A2/en
Publication of WO2009011591A3 publication Critical patent/WO2009011591A3/en
Priority to US14/623,811 priority patent/US20150184203A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/06—Ethanol, i.e. non-beverage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/06—Ethanol, i.e. non-beverage
    • C12P7/08—Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate
    • C12P7/12—Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing sulfite waste liquor or citrus waste
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01016—Ribulokinase (2.7.1.16)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y501/00—Racemaces and epimerases (5.1)
    • C12Y501/03—Racemaces and epimerases (5.1) acting on carbohydrates and derivatives (5.1.3)
    • C12Y501/03004—L-Ribulose-5-phosphate 4-epimerase (5.1.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/01—Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)
    • C12Y503/01004—L-Arabinose isomerase (5.3.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01004—Amidase (3.5.1.4)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • the invention relates to the fields of fermentation technology, molecular biology and biofuel production.
  • the invention relates to an eukaryotic cell having the ability to convert L-arabinose into a fermentation product and to a process for producing a fermentation product wherein this cell is used.
  • EP 1 499 708 discloses the construction of a L-arabinose-fermenting S. cerevisiae strain by overexpression of the bacterial L-arabinose pathway.
  • the enzymes L-arabinose isomerase (araA), L-ribulokinase (araB), and L-ribulose-5- phosphate 4-epimerase (araD) are involved converting L-arabinose to L-ribulose, L- ribulose-5-P, and D-xylulose-5-P, respectively.
  • cerevisiae strain capable of aerobic growth on L-arabinose was obtained.
  • the evolved strain was reported to have acquired a mutation in the L- ribulokinase gene (araB), that resulted in a reduced activity of this enzyme.
  • TALI Enhanced transaldolase
  • EP 1 499 708 discloses that overexpression of the gene encoding the S. cerevisiae galactose permease (GAL2) - also known to transport arabinose - improved growth on arabinose.
  • GAL2 S. cerevisiae galactose permease
  • the evolved S. cerevisiae strain produced ethanol from arabinose at a low specific production rate of 60 - 80 mg h "1 (g dry weight) "1 under oxygen-limited conditions, no anaerobic fermentation of arabinose was observed.
  • the resulting S. cerevisiae strain exhibits a rate of arabinose consumption of 0.70 g h "1 14 (g dry weight) "1 and a rate of ethanol production of 0.29 g h "1 (g dry weight) "1 with an ethanol yield of 0.43 g g "1 during anaerobic growth on L- arabinose as sole carbon source.
  • WO 03/062430 and WO 06/009434 disclose yeast strains able to convert xylose into ethanol. These yeast strains are able to directly isomerise xylose into xylulose. WO 06/096130 discloses yeast strains able to convert xylose and arabinose simultaneously into ethanol.
  • arabinose isomerase (EC 5.3.1.4) is herein defined as an enzyme that catalyses the direct isomerisation of L-arabinose into L-ribulose and vice versa.
  • the enzyme is also known as a L-arabinose ketol-isomerase.
  • Arabinose isomerases of the invention may be further defined by their amino acid sequence as herein described below.
  • arabinose isomerases may be defined by the nucleotide sequences encoding the enzyme as well as by nucleotide sequences hybridising to a reference ⁇ araA) nucleotide sequence encoding a arabinose isomerase as herein described below.
  • a ribulose kinase of the invention may be further defined by its amino acid sequence as herein described below.
  • a ribulose kinase may be defined by the nucleotide sequences encoding the enzyme as well as by nucleotide sequences hybridising to a reference nucleotide sequence (araB) encoding a xylulose kinase as herein described below.
  • L-ribulose-5-phosphate 4-epimerase The enzyme "L-ribulose-5-phosphate 4-epimerase” (5.1.3.4) is herein defined as an enzyme that catalyses the epimerisation of L-ribulose 5-phosphate into D-xylulose 5-phosphate and vice versa.
  • the enzyme is also known as L-ribulose phosphate 4- epimerase or ribulose phosphate 4-epimerase.
  • a ribulose 5-phosphate 4-epimerase of the invention may be further defined by its amino acid sequence as herein described below.
  • ribulose 5-phosphate 4-epimerase may be defined by the nucleotide sequences encoding the enzyme as well as by nucleotide sequences hybridising to a reference nucleotide sequence (araD) encoding a ribulose 5-phosphate 4-epimerase as herein described below.
  • D-ribulose 5-phosphate 3-epimerase The enzyme "D-ribulose 5-phosphate 3-epimerase” (5.1.3.1) is herein defined as an enzyme that catalyses the epimerisation of D-xylulose 5-phosphate into D-ribulose 5-phosphate and vice versa.
  • the enzyme is also known as phosphoribulose epimerase; erythrose-4-phosphate isomerase; phosphoketopentose 3-epimerase; xylulose phosphate 3-epimerase; phosphoketopentose epimerase; ribulose 5-phosphate 3- epimerase; D-ribulose phosphate-3-epimerase; D-ribulose 5-phosphate epimerase; D- ribulose-5-P 3-epimerase; D-xylulose-5-phosphate 3-epimerase; pentose-5-phosphate 3-epimerase; or D-ribulose-5 -phosphate 3-epimerase.
  • Ribulose 5-phosphate isomerase Ribulose 5-phosphate isomerase
  • ribulose 5-phosphate isomerase (EC 5.3.1.6) is herein defined as an enzyme that catalyses direct isomerisation of D-ribose 5-phosphate into D-ribulose 5-phosphate and vice versa.
  • the enzyme is also known as phosphopentosisomerase; phosphoriboisomerase; ribose phosphate isomerase; 5-phosphoribose isomerase; D- ribose 5-phosphate isomerase; D-ribose-5 -phosphate ketol-isomerase; or D-ribose-5- phosphate aldose-ketose-isomerase.
  • transketolase (EC 2.2.1.1) is herein defined as an enzyme that catalyses the reaction: D-ribose 5-phosphate + D-xylulose 5-phosphate into sedoheptulose 7-phosphate + D-glyceraldehyde 3-phosphate and vice versa.
  • the enzyme is also known as glycolaldehydetransferase or sedoheptulose-7-phosphate:D- glyceraldehyde- 3 -phosphate glycolaldehydetransferase.
  • transaldolase (EC 2.2.1.2) is herein defined as an enzyme that catalyses the reaction: sedoheptulose 7-phosphate + D-glyceraldehyde 3-phosphate into D-erythrose 4-phosphate + D-fructose 6-phosphate and vice versa.
  • the enzyme is also known as dihydroxyacetonetransferase; dihydroxyacetone synthase; formaldehyde transketolase; or sedoheptulose-7-phosphate:D-glyceraldehyde-3-phosphate glycerone- transferase.
  • a transaldolase of the invention may be further defined by its amino acid sequence as herein described below. Aldose reductase
  • aldose reductase (EC 1.1.1.21) is herein defined as any enzyme that is capable of reducing an aldose to the corresponding alditol and vice versa.
  • an aldose reductase may be any unspecific aldose reductase that is native (endogenous) to a host cell of the invention and that is capable of reducing aldopentoses such as arabinose, xylose or xylulose to arabinitol or xylitol, respectively.
  • Unspecific aldose reductases catalyse the reaction: aldose + NAD(P)H + H + ⁇ alditol + NAD(P) + .
  • the enzyme has a wide specificity and is also known as aldose reductase; polyol dehydrogenase (NADP + ); alditol:NADP oxidoreductase; alditol:NADP + 1 -oxidoreductase; NADPH-aldopentose reductase; or NADPH-aldose reductase.
  • aldose reductase polyol dehydrogenase (NADP + ); alditol:NADP oxidoreductase; alditol:NADP + 1 -oxidoreductase; NADPH-aldopentose reductase; or NADPH-aldose reductase.
  • a particular example of such an unspecific aldose reductase that is endogenous to S. cerevisiae and that is encoded by the GRE3 gene Troaff et al., 2001, Appl. Environ. Microbiol.
  • Xylose isomerase The enzyme "xylose isomerase” (EC 5.3.1.5) is herein defined as an enzyme that catalyses the direct isomerisation of D-xylose into D-xylulose and vice versa. The enzyme is also known as a D-xylose ketoisomerase. Some xylose isomerases are also capable of catalysing the conversion between D-glucose and D-fructose and are therefore sometimes referred to as glucose isomerase. Xylose isomerases require bivalent cations like magnesium or manganese as cofactor. Xylose isomerases of the invention may be further defined by their amino acid sequence as herein described below.
  • xylose isomerases may be defined by the nucleotide sequences encoding the enzyme as well as by nucleotide sequences hybridising to a reference nucleotide sequence encoding a xylose isomerase as herein described below.
  • a unit (U) of xylose isomerase activity is herein defined as the amount of enzyme producing 1 nmol of xylulose per minute, under conditions as described by Kuyper et al. (2003, FEMS Yeast Res. 4: 69-78).
  • the enzyme is also known as a phosphorylating xylulokinase, D-xylulokinase or ATP:D- xylulose 5 -phosphotransferase. Sequence identity and similarity
  • Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences.
  • similarity between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. "Identity” and “similarity” can be readily calculated by known methods.
  • substantially identical means that two peptide or two nucleotide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default parameters, share at least a certain percentage of sequence identity as defined elsewhere herein.
  • RNA sequences are said to be essentially similar or have a certain degree of sequence identity with DNA sequences, thymine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence.
  • Sequence alignments and scores for percentage sequence identity may be determined using computer programs, such as the GCG Wisconsin Package, Version 10.3, available from Accelrys Inc., 9685 Scranton Road, San Diego, CA 92121-3752 USA or the open-source software Emboss for Windows (current version 2.7.1-07).
  • percent similarity or identity may be determined by searching against databases such as FASTA, BLAST, etc.
  • degree of amino acid similarity the skilled person may also take into account so-called “conservative" amino acid substitutions, as will be clear to the skilled person.
  • Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains.
  • a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine.
  • Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine- valine, and asparagine-glutamine.
  • Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place.
  • the amino acid change is conservative.
  • Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gin or his; Asp to glu; Cys to ser or ala; GIn to asn; GIu to asp; GIy to pro; His to asn or gin; He to leu or val; Leu to ile or val; Lys to arg; gin or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
  • Nucleotide sequences encoding the enzymes of the invention may also be defined by their capability to hybridise with the nucleotide sequences of SEQ ID NO.'s 10 - 18, respectively, under moderate, or preferably under stringent hybridisation conditions.
  • Stringent hybridisation conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridise at a temperature of about 65°C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at 65°C in a solution comprising about 0.1 M salt, or less, preferably 0.2 x SSC or any other solution having a comparable ionic strength.
  • the hybridisation is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution.
  • Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least 50 nucleotides, preferably of about 200 or more nucleotides, to hybridise at a temperature of about 45°C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M salt, preferably 6 x
  • the hybridisation is performed overnight, i.e. at least for 10 hours, and preferably washing is performed for at least one hour with at least two changes of the washing solution.
  • operably linked refers to a linkage of polynucleotide elements in a functional relationship.
  • a nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
  • Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame. Promoter
  • promoter refers to a nucleic acid fragment that functions to control the transcription of one or more genes, located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter.
  • a “constitutive” promoter is a promoter that is active under most environmental and developmental conditions.
  • An “inducible” promoter is a promoter that is active under environmental or developmental regulation. Protein
  • protein or “polypeptide” are used interchangeably and refer to molecules consisting of a chain of amino acids, without reference to a specific mode of action, size, 3-dimensional structure or origin.
  • homologous when used to indicate the relation between a given
  • nucleic acid or polypeptide molecule and a given host organism or host cell, is understood to mean that in nature the nucleic acid or polypeptide molecule is produced by a host cell or organisms of the same species, preferably of the same variety or strain. If homologous to a host cell, a nucleic acid sequence encoding a polypeptide will typically (but not necessarily) be operably linked to another (heterologous) promoter sequence and, if applicable, another (heterologous) secretory signal sequence and/or terminator sequence than in its natural environment. It is understood that the regulatory sequences, signal sequences, terminator sequences, etc. may also be homologous to the host cell.
  • homologous sequence elements allow the construction of "self-cloned" genetically modified organisms (GMO's) (self-cloning is defined herein as in European Directive 98/81/EC Annex II).
  • GMO's genetically modified organisms
  • self-cloning is defined herein as in European Directive 98/81/EC Annex II.
  • homologous means that one single- stranded nucleic acid sequence may hybridize to a complementary single- stranded nucleic acid sequence. The degree of hybridization may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as discussed later.
  • heterologous when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature.
  • Heterologous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but has been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such nucleic acids encode proteins that are not normally produced by the cell in which the DNA is transcribed or expressed.
  • heterologous nucleic acids and proteins may also be referred to as foreign nucleic acids or proteins. Any nucleic acid or protein that one of skill in the art would recognize as heterologous or foreign to the cell in which it is expressed is herein encompassed by the term heterologous nucleic acid or protein.
  • heterologous also applies to non- natural combinations of nucleic acid or amino acid sequences, i.e. combinations where at least two of the combined sequences are foreign with respect to each other.
  • the present invention relates to a eukaryotic cell comprising nucleotide sequences as defined in (a), (b) and (c), whereby the expression of the nucleotide sequences confers to the cell the ability to convert L-arabinose into D- xylulose 5-phosphate.
  • eukaryotic cells that may already have the ability to convert L-arabinose into D-xylulose 5-phosphate (at a low level) and wherein expression of the nucleotide sequences as defined in (a), (b) and (c) increases the cell's ability to convert L-arabinose into D-xylulose 5-phosphate.
  • the ability to convert L-arabinose into D- xylulose 5-phosphate is the ability to convert L-arabinose into D-xylulose 5-phosphate through the subsequent reactions of 1) isomerisation of arabinose into ribulose; 2) phosphorylation of ribulose to ribulose 5-phosphate; and, 3) epimerisation of ribulose 5-phosphate into D-xylulose 5-phosphate.
  • nucleotide sequences confers to, or increases in the cell the ability to grow on arabinose as sole carbon and/or energy source, more preferably expression of the nucleotide sequences confers to the cell, or increases in the ability to grow on arabinose as sole carbon and/or energy source through conversion of arabinose into D-xylulose 5-phosphate (and further metabolism of D-xylulose 5-phosphate).
  • the nucleotide sequence (a) preferably is a nucleotide sequence encoding an arabinose isomerase, preferably a L-arabinose isomerase as herein defined above.
  • the nucleotide sequence encoding the arabinose isomerase preferably is selected from the group consisting of:
  • nucleotide sequence encoding an arabinose isomerase comprising an amino acid sequence that has at least 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 1, 2 and 3;
  • nucleotide sequence comprising a nucleotide sequence that has at least 70, 80,
  • nucleotide sequence the sequences of which differs from the sequence of a nucleotide sequence of (iii) due to the degeneracy of the genetic code.
  • the nucleotide sequence (b) preferably is a nucleotide sequence encoding a ribulokinase, preferably a L-ribulokinase as herein defined above.
  • the nucleotide sequence encoding the ribulokinase preferably is selected from the group consisting of:
  • nucleotide sequence encoding a ribulokinase comprising an amino acid sequence that has at least 55, 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 4, 5 and 6;
  • nucleotide sequence comprising a nucleotide sequence that has at least 65, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the nucleotide sequences of SEQ ID NO's: 13, 14 and 15;
  • nucleotide sequence the sequences of which differs from the sequence of a nucleotide sequence of (iii) due to the degeneracy of the genetic code.
  • the nucleotide sequence (c) preferably is a nucleotide sequence encoding a ribulose-5-P-4-epimerase, preferably a L-ribulose-5-P-4-epimerase as herein defined above.
  • the nucleotide sequence encoding the ribulose-5-P-4-epimerase preferably is selected from the group consisting of: (i) a nucleotide sequence encoding a ribulose-5-P-4-epimerase comprising an amino acid sequence that has at least 55, 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 7, 8 and 9; (ii) a nucleotide sequence comprising a nucleotide sequence that has at least 65, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the nucleotide sequences of SEQ ID NO's: 16, 17 and 18;
  • nucleotide sequence the sequences of which differs from the sequence of a nucleotide sequence of (iii) due to the degeneracy of the genetic code.
  • a nucleotide sequence encoding an arabinose isomerase comprising an amino acid sequence that has at least 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 1, 2 and 3, preferably encodes an amino acid sequence wherein active site residues, and/or residues involved in metal ion- and/or substrate-binding are conserved. Such residues may be derived by comparison of the amino acid sequences of SEQ ID NO's: 1, 2 and 3 with the crystal structure of the E. coli L-arabinose isomerase (Manjasetty and Chance, 2006, J MoI Biol. 360(2):297-309).
  • a nucleotide sequence encoding an L-ribulokinase comprising an amino acid sequence that has at least 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 4, 5 and 6, preferably encodes an amino acid sequence wherein active site residues, and/or residues involved in substrate -binding are conserved. Such residues may be derived by comparison of the amino acid sequences of SEQ ID NO's: 4, 5 and 6 with the crystal structure of the E. coli L-ribulokinase (Lee and Bendet, 1967, Biol Chem. 242(9):2043-50; Lee et al., 1970, J Biol Chem.
  • a nucleotide sequence encoding a ribulose-5-P-4-epimerase comprising an amino acid sequence that has at least 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 7, 8 and 9, preferably encodes an amino acid sequence wherein active site residues, residues involved in metal ion- and substrate-binding and/or residues involved in intersubunit interface are conserved. Such residues may be derived by comparison of the amino acid sequences of SEQ ID NO's: 7, 8 and 9 with the crystal structure of the E. coli ribulose-5-P-4- epimerase (Luo et al., 2001, Biochemistry.
  • the eukaryotic host cell may comprise any possible combination of at least one nucleotide sequence as defined in (a), at least one nucleotide sequence as defined in (b) and at least one nucleotide sequence as defined in (c).
  • nucleotide sequence as defined in (a) can be a nucleotide sequence with a percentage of sequence identity as indicated with an amino acid sequences of an arabinose isomerase (araA) of at least one of Clavibacter michiganensis (C), Arthrobacter aurescens (A) and Gramella forsetii (G);
  • a nucleotide sequence as defined in (b) can be a nucleotide sequence with a percentage of sequence identity as indicated with an amino acid sequences of a L-ribulose kinase (araB) of at least one of Clavibacter michiganensis (C), Arthrobacter aurescens (A) and Gramella forsetii (G);
  • a nucleotide sequence as defined in (c) can be a nucleotide sequence with a percentage of sequence identity as indicated with an amino acid sequences of an ribulose-5-P-4-epimerase (araD) of at least one of Clavibacter michiganens
  • AAA AAA; AAC; AAG; ACA; ACC; ACG; AGA; AGC; AGG; CAA; CAC; CAG; CCA; CCC; CCG; CGA; CGC; CGG; GAA; GAC; GAG; GCA; GCC; GCG; GGA; GGC; GGG.
  • the first position in each triplet indicates the type of the araA sequence
  • the second position indicates the type of araB sequence
  • the third position indicates the type of araD sequence
  • the letters "C”, "A” and “G” indicate amino acid sequences with a percentage amino acid identity as indicated to the corresponding enzymes of Clavibacter michiganensis (C), Arthrobacter aurescens (A) and Gramella forsetii (G), respectively.
  • At least one of the nucleotide sequences as defined in (a), (b) and (c) of claim 1 encodes an amino acid sequences that originate from a bacterial genus selected from the group consisting of Clavibacter, Arthrobacter and Gramella, i.e. the amino acid sequence is identical to an amino acid sequence as it naturally occurs in one of these genera. More preferably, at least one of the nucleotide sequences as defined in (a), (b) and (c) of claim 1 encodes an amino acid sequences that originate from a bacterial species selected from the group consisting of Clavibacter michiganensis, Arthrobacter aurescens and Gramella forsetii, i.e. the amino acid sequence is identical to an amino acid sequence as it naturally occurs in one of these species.
  • the nucleotide sequence encoding these enzymes, as well as other enzymes of the invention are preferably adapted to optimise their codon usage to that of the host cell in question.
  • the adaptiveness of a nucleotide sequence encoding an enzyme to the codon usage of a host cell may be expressed as codon adaptation index (CAI).
  • CAI codon adaptation index
  • the codon adaptation index is herein defined as a measurement of the relative adaptiveness of the codon usage of a gene towards the codon usage of highly expressed genes in a particular host cell or organism.
  • the relative adaptiveness (w) of each codon is the ratio of the usage of each codon, to that of the most abundant codon for the same amino acid.
  • the CAI index is defined as the geometric mean of these relative adaptiveness values. Non-synonymous codons and termination codons (dependent on genetic code) are excluded. CAI values range from 0 to 1, with higher values indicating a higher proportion of the most abundant codons (see Sharp and Li , 1987, Nucleic Acids Research 15: 1281-1295; also see: Jansen et al., 2003, Nucleic Acids Res. ⁇ 31_(8):2242-51).
  • An adapted nucleotide sequence preferably has a CAI of at least 0.2, 0.3, 0.4, 0.5, 0.6 or 0.7. Most preferred are the sequences as listed in SEQ ID NO's: 10 - 18, which have been codon optimised for expression in S. cerevisiae cells.
  • the cell of the invention preferably is a cell capable of active or passive pentose (arabinose and xylose) transport into the cell.
  • the cell preferably contains active glycolysis.
  • the cell further preferably contains an endogenous pentose phosphate pathway.
  • the cell further preferably contains enzymes for conversion of arabinose (and xylose), optionally through pyruvate, to a desired fermentation product such as ethanol, lactic acid, 3 -hydroxy -propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3-propane-diol, ethylene, glycerol, ⁇ -lactam antibiotics and cephalosporins.
  • a particularly preferred cell is a cell that is naturally capable of alcoholic fermentation, preferably, anaerobic alcoholic fermentation.
  • the cell further preferably has a high tolerance to ethanol, a high tolerance to low pH (i.e. capable of growth at a pH lower than 5, 4, or 3) and towards organic acids like lactic acid, acetic acid or formic acid and sugar degradation products such as furfural and hydroxy- methylfurfural, and a high tolerance to elevated temperatures.
  • Any of these characteristics or activities of the cell may be naturally present in the cell or may be introduced or modified by genetic modification, preferably by self cloning or by the methods of the invention described below.
  • a suitable cell is a cultured cell, a cell that may be cultured in fermentation process e.g. in submerged or solid state fermentation.
  • Particularly suitable cells are eukaryotic microorganism like e.g. fungi, however, most suitable for use in the present inventions are yeasts or filamentous fungi.
  • Yeasts are herein defined as eukaryotic microorganisms and include all species of the subdivision Eumycotina (Alexopoulos, C. J., 1962, In: Introductory Mycology, John Wiley & Sons, Inc., New York) that predominantly grow in unicellular form. Yeasts may either grow by budding of a unicellular thallus or may grow by fission of the organism. Preferred yeasts as host cells belong to the genera Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces, and Yarrowia.
  • the yeast is capable of anaerobic fermentation, more preferably anaerobic alcoholic fermentation.
  • anaerobic alcoholic fermentation Over the years suggestions have been made for the introduction of various organisms for the production of bio-ethanol from crop sugars. In practice, however, all major bio-ethanol production processes have continued to use the yeasts of the genus Saccharomyces as ethanol producer. This is due to the many attractive features of Saccharomyces species for industrial processes, i.e., a high acid-, ethanol- and osmo-tolerance, capability of anaerobic growth, and of course its high alcoholic fermentative capacity.
  • Preferred yeast species as fungal host cells include S. cerevisiae, S. exiguus, S. bayanus, K. lactis, K. marxianus and Schizosaccharomyces pombe.
  • Filamentous fungi are herein defined as eukaryotic microorganisms that include all filamentous forms of the subdivision Eumycotina. These fungi are characterized by a vegetative mycelium composed of chitin, cellulose, and other complex polysaccharides.
  • the filamentous fungi of the present invention are morphologically, physiologically, and genetically distinct from yeasts. Vegetative growth by filamentous fungi is by hyphal elongation and carbon catabolism of most filamentous fungi is obligately aerobic.
  • Preferred filamentous fungi as host cells belong to the genera Aspergillus, Trichoderma, Humicola, Acremonium, Fusarium, and Penicillium.
  • the nucleotide sequence as defined in (a), (b) and (c) are preferably operably linked to a promoter that causes sufficient expression of the nucleotide sequences in the cell to confer to the cell the ability to convert L-arabinose into D-xylulose 5 -phosphate.
  • each of the nucleotide sequence as defined in (a), (b) and (c) is operably linked to a promoter that causes sufficient expression of the nucleotide sequences in the cell to confer to the cell the ability to convert L-arabinose into D-xylulose 5-phosphate.
  • the promoter(s) cause sufficient expression of the nucleotide sequences confers to the cell the ability to grow on arabinose as sole carbon and/or energy source, most preferably the promoter(s) cause sufficient expression of the nucleotide sequences confers to the cell the ability to grow on arabinose as sole carbon and/or energy source through conversion of arabinose into D-xylulose 5-phosphate (and further metabolism of D-xylulose 5-phosphate).
  • Suitable promoters for expression of the nucleotide sequence as defined in (a), (b) and (c) include promoters that are insensitive to catabolite (glucose) repression and/or that do require xylose for induction.
  • Promoters having these characteristics are widely available and known to the skilled person. Suitable examples of such promoters include e.g. promoters from glycolytic genes such as the phosphofructokinase (PPK), triose phosphate isomerase (TPI), glyceraldehyde- 3 -phosphate dehydrogenase (GPD, TDH3 or GAPDH), pyruvate kinase (PYK), phosphoglycerate kinase (PGK), glucose-6- phosphate isomerase promoter (PGIl) promoters from yeasts or filamentous fungi; more details about such promoters from yeast may be found in (WO 93/03159).
  • PPK phosphofructokinase
  • TPI triose phosphate isomerase
  • GPD glyceraldehyde- 3 -phosphate dehydrogenase
  • PYK pyruvate kinase
  • PGK phosphogly
  • promoters are ribosomal protein encoding gene promoters, the lactase gene promoter (LAC4), alcohol dehydrogenase promoters (ADHl, ADH4, and the like), the enolase promoter (ENO), the hexose(glucose) transporter promoter (HXT7), and the cytochrome cl promoter (CYCl).
  • lactase gene promoter LAC4
  • alcohol dehydrogenase promoters ADHl, ADH4, and the like
  • ENO enolase promoter
  • HXT7 hexose(glucose) transporter promoter
  • CYCl cytochrome cl promoter
  • promoter that is operably linked to nucleotide sequence as defined in (a), (b) and (c) is homologous to the host cell.
  • each of the nucleotide sequence as defined in (a), (b) and (c) a different promoter is used. This will improved stability of the expression construct by avoiding homologous recombination between repeated promoter sequences and it avoids competition different copies of the promoter for limiting trans-acting factors.
  • a cell of the invention further preferably comprises a genetic modification that increases the flux of the pentose phosphate pathway as described in WO 06/009434.
  • the genetic modification causes an increased flux of the non-oxidative part pentose phosphate pathway.
  • a genetic modification that causes an increased flux of the non-oxidative part of the pentose phosphate pathway is herein understood to mean a modification that increases the flux by at least a factor 1.1, 1.2, 1.5, 2, 5, 10 or 20 as compared to the flux in a strain which is genetically identical except for the genetic modification causing the increased flux.
  • the flux of the non-oxidative part of the pentose phosphate pathway may be measured as described in WO 06/009434.
  • Genetic modifications that increase the flux of the pentose phosphate pathway may be introduced in the cells of the invention in various ways. These including e.g. achieving higher steady state activity levels of xylulose kinase and/or one or more of the enzymes of the non-oxidative part pentose phosphate pathway and/or a reduced steady state level of unspecific aldose reductase activity. These changes in steady state activity levels may be effected by selection of mutants (spontaneous or induced by chemicals or radiation) and/or by recombinant DNA technology e.g. by overexpression or inactivation, respectively, of genes encoding the enzymes or factors regulating these genes.
  • the genetic modification comprises overexpression of at least one enzyme of the (non-oxidative part) pentose phosphate pathway.
  • the enzyme is selected from the group consisting of the enzymes encoding for ribulose-5 -phosphate isomerase, ribulose-5 -phosphate 3-epimerase, transketolase and transaldolase.
  • Various combinations of enzymes of the (non- oxidative part) pentose phosphate pathway may be overexpressed. E.g.
  • the enzymes that are overexpressed may be at least the enzymes ribulose-5-phosphate isomerase and ribulose-5-phosphate 3-epimerase; or at least the enzymes ribulose-5-phosphate isomerase and transketolase; or at least the enzymes ribulose-5-phosphate isomerase and transaldolase; or at least the enzymes ribulose-5-phosphate 3-epimerase and transketolase; or at least the enzymes ribulose-5-phosphate 3-epimerase and transaldolase; or at least the enzymes transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate 3-epimerase, transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate 3-epimerase, transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate isomerase, transketolase and transaldolase; or at least the enzymes
  • each of the enzymes ribulose-5-phosphate isomerase, ribulose-5-phosphate 3-epimerase, transketolase and transaldolase are overexpressed in the cell of the invention.
  • Preferred is a cell in which the genetic modification comprises at least overexpression of the enzyme transaldolase. More preferred is a cell in which the genetic modification comprises at least overexpression of both the enzymes transketolase and transaldolase as such a host cell is already capable of anaerobic growth on arabinose.
  • cells overexpressing only the transketolase and the transaldolase already have the same anaerobic growth rate on arabinose as do cells that overexpress all four of the enzymes, i.e. the ribulose-5-phosphate isomerase, ribulose- 5-phosphate 3-epimerase, transketolase and transaldolase.
  • cells of the invention overexpressing both of the enzymes ribulose-5-phosphate isomerase and ribulose-5-phosphate 3-epimerase are preferred over cells overexpressing only the isomerase or only the 3-epimerase as overexpression of only one of these enzymes may produce metabolic imbalances.
  • an enzyme may be overexpressed by increasing the copynumber of the gene coding for the enzyme in the cell, e.g. by integrating additional copies of the gene in the cell's genome, by expressing the gene from an episomal multicopy expression vector or by introducing an episomal expression vector that comprises multiple copies of the gene.
  • the coding sequence used for overexpression of the enzymes preferably is homologous to the host cell of the invention. However, coding sequences that are heterologous to the host cell of the invention may likewise be applied.
  • overexpression of enzymes in the cells of the invention may be achieved by using a promoter that is not native to the sequence coding for the enzyme to be overexpressed, i.e. a promoter that is heterologous to the coding sequence to which it is operably linked.
  • a promoter that is heterologous to the coding sequence to which it is operably linked
  • the promoter is also preferred that the promoter is homologous, i.e. endogenous to the cell of the invention.
  • the heterologous promoter is capable of producing a higher steady state level of the transcript comprising the coding sequence (or is capable of producing more transcript molecules, i.e.
  • Suitable promoters in this context include promoters as described above for expression of the nucleotide sequences as defined in (a), (b) and
  • a further preferred cell of the invention comprises a genetic modification that reduces unspecific aldose reductase activity in the cell.
  • unspecific aldose reductase activity is reduced in the host cell by one or more genetic modifications that reduce the expression of or inactivates a gene encoding an unspecific aldose reductase.
  • the genetic modifications reduce or inactivate the expression of each endogenous copy of a gene encoding an unspecific aldose reductase that is capable of reducing an aldopentose, including arabinose, xylose and xylulose, in the cell's genome.
  • a given cell may comprise multiple copies of genes encoding unspecific aldose reductases as a result of di-, poly- or aneu-ploidy, and/or a cell may contain several different (iso)enzymes with aldose reductase activity that differ in amino acid sequence and that are each encoded by a different gene. Also in such instances preferably the expression of each gene that encodes an unspecific aldose reductase is reduced or inactivated.
  • the gene is inactivated by deletion of at least part of the gene or by disruption of the gene, whereby in this context the term gene also includes any non-coding sequence up- or down-stream of the coding sequence, the (partial) deletion or inactivation of which results in a reduction of expression of unspecific aldose reductase activity in the host cell.
  • a nucleotide sequence encoding an aldose reductase whose activity is to be reduced in the cell of the invention and amino acid sequences of such aldose reductases are described in WO 06/009434 and include e.g. the (unspecific) aldose reductase genes of S. cerevisiae GRE3 gene (Traff et al., 2001, Appl. Environm. Microbiol. 67: 5668-5674) and orthologues thereof in other species.
  • the cell of the invention that has the ability to convert L-arabinose into D-xylulose 5-phosphate expressing in addition has the ability of isomerising xylose to xylulose as e.g. described in WO 03/0624430 and in WO 06/009434.
  • the ability of isomerising xylose to xylulose is preferably conferred to the cell by transformation with a nucleic acid construct comprising a nucleotide sequence encoding a xylose isomerase.
  • the cell thus acquires the ability to directly isomerise xylose into xylulose.
  • the cell thus acquires the ability to grow aerobically and/or anaerobically on xylose as sole energy and/or carbon source though direct isomerisation of xylose into xylulose (and further metabolism of xylulose).
  • direct isomerisation of xylose into xylulose occurs in a single reaction catalysed by a xylose isomerase, as opposed to the two step conversion of xylose into xylulose via a xylitol intermediate as catalysed by xylose reductase and xylitol dehydrogenase, respectively.
  • xylose isomerases (and their amino acid and coding nucleotide sequences) that may be successfully used to confer to the cell of the invention the ability to directly isomerise xylose into xylulose have been described in the art. These include the xylose isomerase of Piromyces sp. and of other anaerobic fungi that belongs to the families Neocallimastix, Caecomyces, Piromyces, Orpinomyces, or Ruminomyces (WO 03/0624430), the xylose isomerase of the bacterial genus Bacteroides, including e.g. B. thetaiotaomicron (WO 06/009434) and B.
  • a xylose isomerase that may be used to confer to the cell of the invention the ability to directly isomerise xylose into xylulose is a xylose isomerase comprising an amino acid sequence that has at least 70, 75, 80, 83% amino acid identity with the amino acid sequence of SEQ ID NO. 19 or 20.
  • the cell of the invention that has the ability of isomerising xylose to xylulose further preferably comprises xylulose kinase activity so that xylulose isomerised from xylose may be metabolised to pyruvate.
  • the cell contains endogenous xylulose kinase activity.
  • a cell of the invention comprises a genetic modification that increases the specific xylulose kinase activity.
  • the genetic modification causes overexpression of a xylulose kinase, e.g. by overexpression of a nucleotide sequence encoding a xylulose kinase.
  • the gene encoding the xylulose kinase may be endogenous to the cell or may be a xylulose kinase that is heterologous to the cell.
  • a nucleotide sequence that may be used for overexpression of xylulose kinase in the cells of the invention is e.g. the xylulose kinase gene from S. cerevisiae (XKSl) as described by Deng and Ho (1990, Appl. Biochem. Biotechnol. 24-25: 193-199).
  • xylulose kinase is a xylose kinase that is related to the xylulose kinase from Piromyces (xylB; see WO 03/0624430).
  • This Piromyces xylulose kinase is actually more related to prokaryotic kinase than to all of the known eukaryotic kinases such as the yeast kinase.
  • the eukaryotic xylulose kinases have been indicated as nonspecific sugar kinases, which have a broad substrate range that includes xylulose.
  • xylulose kinases to which the Piromyces kinase is most closely related, have been indicated to be more specific kinases for xylulose, i.e. having a narrower substrate range.
  • a xylulose kinase to be overexpressed is overexpressed by at least a factor 1.1, 1.2, 1.5, 2, 5, 10 or 20 as compared to a strain which is genetically identical except for the genetic modification causing the overexpression. It is to be understood that these levels of overexpression may apply to the steady state level of the enzyme's activity, the steady state level of the enzyme's protein as well as to the steady state level of the transcript coding for the enzyme.
  • the cells according to the invention may comprises further genetic modifications that result in one or more of the characteristics selected from the group consisting of (a) increased transport of arabinose and/or xylose into the cell; (b) decreased sensitivity to catabolite repression; (c) increased tolerance to ethanol, osmolarity or organic acids; and, (e) reduced production of by-products.
  • By-products are understood to mean carbon-containing molecules other than the desired fermentation product and include e.g. arabinitol, xylitol, glycerol and/or acetic acid.
  • Any genetic modification described herein may be introduced by classical mutagenesis and screening and/or selection for the desired mutant, or simply by screening and/or selection for the spontaneous mutants with the desired characteristics.
  • the genetic modifications may consist of overexpression of endogenous genes and/or the inactivation of endogenous genes.
  • Genes the overexpression of which is desired for increased transport of arabinose and/or xylose into the cell are preferably chosen form genes encoding a hexose or pentose transporter.
  • these genes include HXTl, HXT2, HXT4, HXT5, HXT7 and GAL2, of which HXT7, HXT5 and GAL2 are most preferred (see Sedlack and Ho, Yeast 2004; 21: 671-684).
  • orthologues of these genes in other species may be overexpressed.
  • Other genes that may be overexpressed in the cells of the invention include genes coding for glycolytic enzymes and/or ethanologenic enzymes such as alcohol dehydrogenases.
  • Preferred endogenous genes for inactivation include hexose kinase genes e.g. the S. cerevisiae HXK2 gene (see Diderich et al., 2001, Appl. Environ. Microbiol. 67: 1587-1593); the S. cerevisiae MIGl or MIG2 genes; genes coding for enzymes involved in glycerol metabolism such as the S. cerevisiae glycerol-phosphate dehydrogenase 1 and/or 2 genes; or (hybridising) orthologues of these genes in other species.
  • hexose kinase genes e.g. the S. cerevisiae HXK2 gene (see Diderich et al., 2001, Appl. Environ. Microbiol. 67: 1587-1593); the S. cerevisiae MIGl or MIG2 genes; genes coding for enzymes involved in glycerol metabolism such as the S. cere
  • any of the genetic modifications of the cells of the invention as described herein are, in as far as possible, preferably introduced or modified by self cloning genetic modification.
  • a preferred cell of the invention with one or more of the genetic modifications described above, including modifications obtained by selection of (spontaneous) mutants, has the ability to grow on L-arabinose and optionally xylose as carbon/energy source, preferably as sole carbon source, and preferably under anaerobic conditions.
  • the cell produces essentially no arabinitol, e.g. the arabinitol produced is below the detection limit or e.g. less than 5, 2, 1, 0.5, or 0.3 % of the carbon consumed on a molar basis.
  • the cell produces essentially no xylitol, e.g. the xylitol produced is below the detection limit or e.g. less than 5, 2, 1, 0.5, or 0.3 % of the carbon consumed on a molar basis.
  • a cell of the invention preferably has the ability to grow on L-arabinose as sole carbon/energy source at a rate of at least 0.01, 0.02, 0.05, 0.1, 0.2, 0,25 or 0,3 h "1 under aerobic conditions, or, more preferably, at a rate of at least 0.005, 0.01, 0.02, 0.05, 0.08, 0.1, 0.12, 0.15 or 0.2 h "1 under anaerobic conditions.
  • a cell of the invention preferably has the ability to grow on a mixture of glucose and L-arabinose (in a 1: 1 weight ratio) as sole carbon/energy source at a rate of at least 0.01, 0.02, 0.05, 0.1, 0.2, 0,25 or 0,3 h "1 under aerobic conditions, or, more preferably, at a rate of at least 0.005, 0.01, 0.02, 0.05, 0.08, 0.1, 0.12, 0.15 or 0.2 h "1 under anaerobic conditions.
  • a cell of the invention has a specific L-arabinose consumption rate of at least 346, 400, 600, 700, 800, 900 or 1000 mg h "1 (g dry weight) "1 .
  • a cell of the invention has a yield of fermentation product (such as ethanol) on L-arabinose that is at least 20, 40, 50, 60, 80, 90, 95 or 98% of the cell's yield of fermentation product (such as ethanol) on glucose.
  • the modified host cell's yield of fermentation product (such as ethanol) on L-arabinose is equal to the host cell's yield of fermentation product (such as ethanol) on glucose.
  • the modified host cell's biomass yield on L-arabinose is preferably at least 55, 60, 70, 80, 85, 90, 95 or 98% of the host cell's biomass yield on glucose. More preferably, the modified host cell's biomass yield on L-arabinose is equal to the host cell's biomass yield on glucose. It is understood that in the comparison of yields on glucose and L-arabinose both yields are compared under aerobic conditions or both under anaerobic conditions.
  • the invention in another aspect relates to a eukaryotic cell comprising nucleotide sequences as encoding (a 1 ) an arabinose isomerase, (b 1 ) a xylulose kinase, and (c 1 ) a ribulose-5-P-4-epimerase, whereby the expression of the nucleotide sequences confers to the cell the ability to convert L-arabinose into D-xylulose 5 -phosphate.
  • the broad substrate specificity of xylulose kinases in particular eukaryotic xylulose kinases, is exploited to phosphorylate ribulose (and optionally xylulose).
  • eukaryotic cells that may already have the ability to convert L-arabinose into D-xylulose 5-phosphate (at a low level) and wherein expression of the nucleotide sequences as defined in (a 1 ), (b 1 ) and (c 1 ) increases the cell's ability to convert L-arabinose into D-xylulose 5-phosphate.
  • the ability to convert L-arabinose into D- xylulose 5-phosphate is the ability to convert L-arabinose into D-xylulose 5-phosphate through the subsequent reactions of 1) isomerisation of arabinose into ribulose; 2) phosphorylation of ribulose to ribulose 5-phosphate; and, 3) epimerisation of ribulose 5-phosphate into D-xylulose 5-phosphate.
  • nucleotide sequences confers to, or increases in the cell the ability to grow on arabinose as sole carbon and/or energy source, more preferably expression of the nucleotide sequences confers to the cell, or increases in the ability to grow on arabinose as sole carbon and/or energy source through conversion of arabinose into D-xylulose 5-phosphate (and further metabolism of D-xylulose 5-phosphate).
  • the nucleotide sequence (a 1 ) encoding the arabinose isomerase may be a nucleotide sequence (a) as defined above, however the nucleotide sequence may also encode any other, preferably bacterial, arabinose isomerase, e.g. those from E. coli, Bacillus and Lactobacillus as described in e.g. EP 1499708 and Wisselink et al. (2007, supra).
  • the nucleotide sequence encoding the arabinose isomerase comprises an amino acid sequence that has at least 30, 35, 40, 45, or 50% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 1, 2 and 3.
  • the nucleotide sequence (b 1 ) encoding a polypeptide with xylulose kinase activity preferably comprises an amino acid sequence having at least 50, 60, 70, 80, 90 or 95% identity with SEQ ID NO. 21.
  • the nucleotide sequence (c 1 ) encoding the ribulose-5-P-4-epimerase may be a nucleotide sequence (c) as defined above, however the nucleotide sequence may also encode any other, preferably bacterial, ribulose-5-P-4-epimerase, e.g. those from E. coli, Bacillus and Lactobacillus as described in e.g. EP 1499708 and Wisselink et al. (2007, supra).
  • the nucleotide sequence encoding the ribulose-5-P-4- epimerase comprises an amino acid sequence that has at least 30, 35, 40, 45, or 50% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 7, 8 and 9.
  • the eukaryotic cell comprising the nucleotide sequence encoding an eukaryotic xylulose kinase, in stead of a bacterial ribulose kinase, may the same as the above described cells comprising the nucleotide sequence encoding a bacterial ribulose kinase sequences in all aspects except for the more broadly defined nucleotide sequences (a 1 ) and (c 1 ) and the different nucleotide sequence (b 1 ).
  • the invention in another aspect relates to a process for producing a fermentation product selected from the group consisting of ethanol, lactic acid, 3 -hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3-propane-diol, ethylene, glycerol, ⁇ -lactam antibiotics and cephalosporins.
  • the process preferably comprises the steps of: a) fermenting a medium containing a source of arabinose, and optionally xylose, with a cell as defined hereinabove, whereby the cell ferments arabinose, and optionally xylose, to the fermentation product, and optionally, b) recovery of the fermentation product.
  • the carbon source in the fermentation medium may also comprise a source of glucose.
  • the fermentation medium may further also comprise other types of carbohydrates such as e.g. in particular a source of xylose.
  • the sources of arabinose, glucose and xylose may be arabinose, glucose and xylose as such (i.e. as monomelic sugars) or they may be in the form of any carbohydrate oligo- or polymer comprising arabinose, glucose and/or xylose units, such as e.g. lignocellulose, arabinans, xylans, cellulose, starch and the like.
  • carbohydrases For release of arabinose, glucose and/or xylose units from such carbohydrates, appropriate carbohydrases (such as arabinases, xylanases, glucanases, amylases, cellulases, glucanases and the like) may be added to the fermentation medium or may be produced by the modified host cell. In the latter case the modified host cell may be genetically engineered to produce and excrete such carbohydrases.
  • An additional advantage of using oligo- or polymeric sources of glucose is that it enables to maintain a low(er) concentration of free glucose during the fermentation, e.g. by using rate- limiting amounts of the carbohydrases preferably during the fermentation.
  • the modified host cell ferments both the arabinose and glucose, and optionally xylose, preferably simultaneously in which case preferably a modified host cell is used which is insensitive to glucose repression to prevent diauxic growth.
  • the fermentation medium will further comprise the appropriate ingredient required for growth of the modified host cell.
  • Compositions of fermentation media for growth of eukaryotic microorganisms such as yeasts and filamentous fungi are well known in the art.
  • the fermentation process may be an aerobic or an anaerobic fermentation process.
  • An anaerobic fermentation process is herein defined as a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than 5, 2.5 or 1 mmol/L/h, more preferably 0 mmol/L/h is consumed (i.e. oxygen consumption is not detectable), and wherein organic molecules serve as both electron donor and electron acceptors.
  • substantially no oxygen preferably less than 5, 2.5 or 1 mmol/L/h, more preferably 0 mmol/L/h is consumed (i.e. oxygen consumption is not detectable)
  • organic molecules serve as both electron donor and electron acceptors.
  • NADH produced in glycolysis and biomass formation cannot be oxidised by oxidative phosphorylation.
  • pyruvate or one of its derivatives as an electron and hydrogen acceptor thereby regenerating NAD + .
  • pyruvate is used as an electron (and hydrogen acceptor) and is reduced to fermentation products such as ethanol, lactic acid, 3-hydroxy- propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3- propane-diol, ethylene, glycerol, ⁇ -lactam antibiotics and cephalosporins.
  • Anaerobic processes of the invention are preferred over aerobic processes because anaerobic processes do not require investments and energy for aeration and in addition, anaerobic processes produce higher product yields than aerobic processes.
  • the fermentation process of the invention may be run under aerobic oxygen-limited conditions.
  • the rate of oxygen consumption is at least 5.5, more preferably at least 6 and even more preferably at least 7 mmol/L/h.
  • the fermentation process is preferably run at a temperature that is optimal for the modified cells of the invention.
  • the fermentation process is performed at a temperature which is less than 42°C, preferably less than 38°C.
  • the fermentation process is preferably performed at a temperature which is lower than 35, 33, 30 or 28°C and at a temperature which is higher than 20, 22, or 25°C.
  • the cells stably maintain the nucleic acid constructs that confer to the cell the ability of converting arabinose into D-xylulose 5 -phosphate, and optionally isomerising xylose to xylulose.
  • the cells Preferably in the process at least 10, 20, 50 or 75% of the cells retain the abilities to convert arabinose into D-xylulose 5-phosphate, and optionally isomerise xylose to xylulose after 50 generations of growth, preferably under industrial fermentation conditions.
  • a preferred fermentation process is a process for the production of ethanol, whereby the process comprises the steps of: a) fermenting a medium containing a source of arabinose, and optionally xylose, with a cell as defined hereinabove, whereby the cell ferments arabinose, and optionally xylose, to ethanol, and optionally, b) recovery of the ethanol.
  • the fermentation medium may further be performed as described above.
  • the volumetric ethanol productivity is preferably at least 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0 or 10.0 g ethanol per litre per hour.
  • the ethanol yield on arabinose and/or glucose and/or xylose in the process preferably is at least 50, 60, 70, 80, 90, 95 or 98%.
  • the ethanol yield is herein defined as a percentage of the theoretical maximum yield, which, for arabinose, glucose and xylose is 0.51 g. ethanol per g. arabinose, glucose or xylose.
  • a further preferred fermentation process is a process which comprises fermenting a medium containing a source of arabinose and a source of xylose wherein however two separate strains of cells are used, a first strain of cells as defined hereinabove except that cells of the first strain do not have the ability to (directly) isomerise xylose into xylulose, which cells of the first strain ferment arabinose to the fermentation product; and a second strain of cells as defined hereinabove except that cells of the second strain do not have the ability to convert arabinose to xylulose 5 -phosphate, which cells of the second strain ferment xylose to the fermentation product.
  • the process optionally comprises the step of recovery of the fermentation product.
  • the cells of the first and second are further as otherwise described hereinabove.
  • Example 1 Plasmids
  • araA For high level of expression of the bacterial araA and araD genes the corresponding expression cassettes are inserted into the 2 ⁇ plasmid pAKX002 that already comprises the Piromyces xylA gene linked the S. cerevisiae TPI promoter.
  • the araA expression cassettes is constructed by amplifying the S. cerevisiae TDH3 promoter (Pmm) with oligo's that allow to link the TDH3 promoter to the 5' end of the synthetic araA coding sequences of Arthrobacter aurescens (SEQ ID NO. 10), Clavibacter michiganensis (SEQ ID NO. 11) and Gramella forsetii (SEQ ID NO. 12), and amplifying the S.
  • ADHl terminator with oligo's that allow to link the 3' end of the synthetic araA coding sequences to the ADHl terminator (T ADHI )-
  • T ADHI ADHl terminator
  • the two fragments are extracted from gel and mixed in roughly equimolar amounts with the fragments of the synthetic araA coding sequences.
  • a PCR is performed using the 5' P TDH 3 oligo and the 3' T ADHI oligo.
  • the resulting V T DH3-araA-T ADHI cassette is gel purified, cut at the 5 'and 3' restriction sites and then ligated into pAKX002, resulting in plasmids pRN-AAaraA, pRN-CMaraA and pRN-GFaraA, respectively.
  • the three araD constructs are made by first amplifying a truncated version of the S. cerevisiae HXT7 promoter (? HXT7 ) with oligo's that allow to link the HXT7 promoter to the 5' end of the synthetic araD coding sequences of Arthrobacter aurescens (SEQ ID NO. 16), Clavibacter michiganensis (SEQ ID NO. 17) and Gramella forsetii (SEQ ID NO. 18), and amplifying the PGIl terminator with oligo's that allow to link the 3' end of the synthetic araD coding sequences to the PGIl terminator region (TV G/ ).
  • the resulting fragments were extracted from gel and mixed in roughly equimolar amounts with the synthetic araD coding sequences, after which a PCR was performed using the 5' PfflT7 oligo and the 3' T ⁇ G/ oligo.
  • the resulting Vjix ⁇ -araD-TpGii cassettes are gel purified, cut at the 5 'and 3' restriction sites and ligated into pRN-AAaraA, pRN- CMaraA and pRN-GFaraA, respectively, resulting in plasmids pRN-AAaraAD, pRN- CMaraAD and pRN-GFaraAD, respectively.
  • the integrational plasmid pRS305 is used (Gietz and Sugino, 1988, Gene 74:527-534).
  • the S.cerevisiae XKSl gene was also included on this vector.
  • the V ADHI - XKSl -T c Y ci containing Pvul fragment from p415 ADHXKS was ligated into the Pvul digested vector backbone from the integration plasmid pRS305, resulting in pRN- XKSl.
  • araB genes For expression of the bacterial araB genes, three cassettes containing the synthetic araB coding sequences of Arthrobacter aurescens (SEQ ID NO. 13), Clavibacter michiganensis (SEQ ID NO. 14) and Gramella forsetii (SEQ ID NO. 15) genes between the PGIl promoter (Pp ⁇ i) and ADHl terminator (T ADHI ) is constructed by PCR amplification.
  • the AraB expression cassettes are made by amplifying the PGIl promoter with oligonucleotides that allow to link the PGIl promoter to the 5' end of the synthetic araB coding sequences, and amplifying the ADHl terminator with oligo's that allow to link the 3' end of the synthetic araB coding sequences to the ADHl terminator (T ADHI )-
  • the resulting Ppc ⁇ -araB-TADHi cassettes are gel purified, digested at the 5'and 3' restriction sites and are then ligated into pRN-XKSl, to yield plasmids pRN-XKSl- AAaraB, pRN-XKSl-CMaraB and pRN-XKSl-GFaraB, respectively.
  • RWB217 has the following genotype: MATA ura3-52 Ieu2-112 loxP-PTPI::(-266,-l)TALl gre3::hphMX pUGPTPI-TKLl pUGPTPI-RPEl KanloxP-PTPI: :(-?,- I)RKIl ⁇ p415ADHXKS, pAKX002 ⁇ .
  • Strain RWB218 is obtained by selection of RWB217 for improved growth on D-xylose (Kuyper et al., 2005b, FEMS Yeast Res. 5:925-934) by plating and restreaking on MYD plates.
  • RWB218 is grown non- selectively on YPD in order to facilitate the loss of plasmids pAKX002 and p415ADHXKSl (Kuyper et al., 2005a, supra), harbouring the URA3 and LEU2 selective markers, respectively.
  • RWB218 is plated on YPD, single colonies are screened for plasmid loss by testing for uracil and leucine auxotrophy.
  • RN679 A strain that has lost both the KanMX marker and the pSH47 plasmid is designated as RN679.
  • the genotype of RN679 is: MATA ura3-52 Ieu2-112 loxP-PTPI::(-266,-l)TALl gre3::hphMX pUGPTPI-TKLl pUGPTPI-RPEl KanloxP-PTPI::(-?,-l)RKIl.
  • Strains RN680, RN681 and RN682 do not grow on solid synthetic medium supplemented with 2% (w/v) L-arabinose (MYA). Therefore, evolutionary engineering is applied for the selection of cells of the strains RN680, RN681 and RN682 with an improved specific growth rate on arabinose.
  • synthetic medium supplemented with 2% of arabinose Prior to the selection in synthetic medium supplemented with 2% of arabinose, cells are pre-grown in synthetic medium with galactose, as it is known that galactose-induced S. cerevisiae cells can transport L- arabinose via the galactose permease GAL2p (Kou et al., 1970, J. Bacterid. 103:671- 67817).
  • Galactose-grown cells of strains RN680, RN681, RN682 and control strain RWB218 are transferred to shake flasks containing MY supplemented with 0.1% D- galactose and 2% L-arabinose. After approximately several weeks of cultivation in the single initial shake flask, the cultures of strains RN680, RN681, RN682 IMSOOOl show very slow growth after depletion of the galactose, in contrast to the reference strain RWB218 which does not grow after depletion of galactose. Cells of the cultures are next transferred to fresh synthetic medium supplied with 2% of L-arabinose (MYA).
  • MYA L-arabinose
  • strains RN680, RN681, RN682 grow with an improved doubling time, whereas strain RWB219 still does not grow.
  • Next cells are sequentially transferred each time an OD660 of 2-3 is reached to fresh MYA with a start OD660 of approximately 0.05 and gradually the specific growth rate of the sequentially transferred cultures increases.
  • the aerobically evolved strains are first grown under oxygen-limited conditions. As soon as growth is observed under oxygen-limited conditions, the culture is switched to anaerobic conditions in the next batch cycle. Upon arabinose depletion, as indicated by the CO 2 percentage dropping below 0.05% after the CO 2 production peak, a new cycle is initiated by either manual or automated replacement of approximately 90% of the culture with fresh synthetic medium containing 20 g I "1 L- arabinose. In 10-15 cycles, the anaerobic specific growth rate increases as estimated from the CO 2 profile. After 20-25 cycles no significant further increase of the growth rate is noticed. Single colonies are isolated on solid MYA for anaerobically evolved descendants of each of RN680, RN681 and RN682.
  • araB ribulokinase EC 2.7.1.16
  • the 9 genes were synthesized by EXONBIO based on sequences that were optimized for codon usage in yeast by Nextgen Sciences. See sequence listings.
  • the yeast host strain was RNlOOO. This strain is a derivative of strain RWB 218 (Kuyper et al., FEMS Yeast Research 5, 2005, 399-409). The plasmid pAKX002 encoding the Piromyces XyIA is lost in RNlOOO.
  • the genotype of the host strain is: MatA, ura3-52, Ieu2-112, gre3::hphMX, loxP-Ptpi::TALl, KanloxP-Ptpi::RKIl, pUGPtpi-TKLl, pUGPtpi-RPEl, ⁇ p415 PadhlXKSlTcycl-LEU2J
  • the synthetic genes were amplified using the 'polymerase chain reaction (PCR) 'technique facilitating cloning. For each reaction two short synthetic oligomers 'primers' were used. The one in the 'forward' and the other in the 'reverse' mode. Constitutive promoter sequences and terminator sequences from Saccharomyces cerevisiae were also amplified using PCR. In Table 1 an overview of all primers used in this study is given. To minimize PCR-induced sequence mistakes, the Finnzymes proofreading enzyme Phusion was used.
  • the plasmid used to express the ara genes into yeast is pRS316 (Sikorski R.S., Hieter P., "A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae” Genetics 122:19-27(1989), accession U03442, ATCC77145).
  • This plasmid is a centromeric plasmid (low copynumber in yeast) that has the URA3 gene for selection.
  • the construction of the pRS316 GGA plasmid is given below.
  • the primers used contained specific restriction-enzyme recognition sites. Construction involved standard molecular biological techniques. GaraA: promoter cut with Notl and Pstl; ORF cut with Pstl and Xhol; terminator cut with Xhol and 55/WI.
  • GaraB promoter cut with Agel and Xbal; ORF cut with Xbal and BssHll; terminator cut with BssHII and 55/WI.
  • the expression constructs were first assembled per gene and than ligated together into the plasmid pRS316 cut with Notl and Xhol. A and B in opposite direction (adjacent terminator sequences), B and D in opposite direction (adjacent promoter sequences).
  • a physical map of the final plasmid p RS316 GGA is shown in Figure 1 and its sequence is depicted in SEQ ID NO: 22.
  • Other combinations of AraA, AraB and AraD including the respective promoters were obtained as well and corresponding plasmids were constructed.
  • strain RN 1002 has the ability to grow at the expense of L-arabinose under oxic (aerobic) conditions.
  • Yeast nitrogen base (YNB, Difco) buffered with 0.17M KH 2 PO 4 and 0.72M K 2 HPO 4 at pH 5,5 was used for assessing oxic growth at the expense of arabinose. Incubation were performed in the presence of galactose in order to stimulate cell biomass production. After heat sterilization of the medium for 20 min at 120 0 C, the sugars galactose (0.05%) and/or L-arabinose (1%) were added after filter sterilization.
  • strain RN1002 has the ability to metabolize L-arabinose as witnessed by the consumption of L-arabinose and to grow at its expense as demonstrated by the increase in time of OD values of the L-arabinose-containing culture.
  • strain RN 1002 has the ability to produce ethanol from L-arabinose under anoxic (anaerobic) conditions.
  • a medium containing yeast extract (1% w/w) and peptone (2% w/w) was used. After heat sterilization of the medium for 20 min at 120 0 C, the sugars galactose(0.5%) and/or arabinose(2%) were added separately after heat sterilization at 110 0 C.
  • strain RN1002 was grown at 32 0 C and pH5 in a shake flask culture on 100 ml medium containing yeast extract with peptone and with addition of the sugars galactose (0.5%) and arabinose (2%). After 70 h incubation, this culture was centrifuged twice and cells were resuspended to an OD of 112. This suspension was used to inoculate four anoxic operated stirred fermenters (BAM fermenters purchased from Halotec) with 1 ml each. The subsequent batch fermentations were performed at 32 0 C and the working volumes of the four fermentations used in this study were 150 ml each.
  • BAM fermenters purchased from Halotec
  • the exhaust gas was cooled by a condenser connected to a cryostat set at 4°C.
  • the exhaust gas flow rate was measured with a Brooks Smart mass flow meter, which is calibrated for CO 2 flow. This mass flow meter was located in a valve box interface (Halotec).
  • the valve box contains all the mechanical parts of the system and its purpose is to control the gas flow of each flask and to house the sensors.
  • Optical densities were analyzed by an (Perkin Elmer lambda 2S) spectrophotometer at 700 nm.
  • Ethanol concentrations in filtered supernatants were determined by HPLC analysis with a Bio-rad Aminex HPX-87H column at 65°C. The column was eluted with 0.25 M sulfuric acid at a flow rate of 0.55 ml min "1 . 2.6.6 Determination of monomeric sugars

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to eukaryotic cells which have the ability to convert L-arabinose into D-xylulose 5-phosphate. The cells have acquired this ability by transformation with nucleotide sequences coding for an arabinose isomerase, a ribulokinase, and a ribulose-5-P-4-epimerase from a bacterium that belongs to a Clavibacter, Arthrobacter or Gramella genus. The cell preferably is a yeast or a filamentous fungus, more preferably a yeast is capable of anaerobic alcoholic fermentation. The may further comprise one or more genetic modifications that increase the flux of the pentose phosphate pathway, reduce unspecific aldose reductase activity, confer to the cell the ability to directly isomerise xylose into xylulose, increase the specific xylulose kinase activity, increase transport of at least one of xylose and arabinose into the host cell, decrease sensitivity to catabolite repression, increase tolerance to ethanol, osmolarity or organic acids; and/or reduce production of by- products. The cell preferably is a cell that has the ability to produce a fermentation product such as ethanol, lactic acid, 3-hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3-propane-diol, ethylene, glycerol, -lactam antibiotics and cephalosporins. The invention further relates to processes for producing these fermentation products wherein a cell of the invention is used to ferment arabinose into the fermentation products.

Description

Novel arabinose-fermenting eukaryotic cells
Field of the invention The invention relates to the fields of fermentation technology, molecular biology and biofuel production. In particular the invention relates to an eukaryotic cell having the ability to convert L-arabinose into a fermentation product and to a process for producing a fermentation product wherein this cell is used.
Background of the invention
Economically viable ethanol production from the hemicellulose fraction of plant biomass requires the simultaneous conversion of both pentoses and hexoses at comparable rates and with high yields. Yeasts, in particular Saccharomyces spp., are the most appropriate candidates for this process since they can grow fast on hexoses, both aerobically and anaerobically. Furthermore they are much more resistant to the toxic environment of lignocellulose hydrolysates than (genetically modified) bacteria. Although wild-type S. cerevisiae strains rapidly ferment hexoses with high efficiency, they cannot grow on nor use pentoses such as D-xylose and L-arabinose. This inspired various studies to expand the substrate range of S. cerevisiae. EP 1 499 708 discloses the construction of a L-arabinose-fermenting S. cerevisiae strain by overexpression of the bacterial L-arabinose pathway. In the bacterial pathway, the enzymes L-arabinose isomerase (araA), L-ribulokinase (araB), and L-ribulose-5- phosphate 4-epimerase (araD) are involved converting L-arabinose to L-ribulose, L- ribulose-5-P, and D-xylulose-5-P, respectively. Using the Bacillus subtilis araA gene and the Escherichia coli araB, and araD genes, combined with evolutionary engineering, a S. cerevisiae strain capable of aerobic growth on L-arabinose was obtained. The evolved strain was reported to have acquired a mutation in the L- ribulokinase gene (araB), that resulted in a reduced activity of this enzyme. Enhanced transaldolase (TALI) activity was also reported to be required for L-arabinose fermentation. Moreover, EP 1 499 708 discloses that overexpression of the gene encoding the S. cerevisiae galactose permease (GAL2) - also known to transport arabinose - improved growth on arabinose. However, although the evolved S. cerevisiae strain produced ethanol from arabinose at a low specific production rate of 60 - 80 mg h"1 (g dry weight)"1 under oxygen-limited conditions, no anaerobic fermentation of arabinose was observed.
Wisselink et al. (2007, AEM Accepts, published online ahead of print on 1 June
2007; Appl. Environ. Microbiol. doi:10.1128/AEM.00177-07) disclose a S. cerevisiae strain obtained by expression of the L-arabinose isomerase (araA), L-ribulokinase
(araB), and L-ribulose-5-phosphate 4-epimerase (araD) of the L-arabinose utilization pathway of Lactobacillus plantarum, overexpression of S. cerevisiae genes encoding the enzymes of the non-oxidative pentose-phosphate pathway, and extensive evolutionary engineering. The resulting S. cerevisiae strain exhibits a rate of arabinose consumption of 0.70 g h"1 14 (g dry weight)"1 and a rate of ethanol production of 0.29 g h"1 (g dry weight)"1 with an ethanol yield of 0.43 g g"1 during anaerobic growth on L- arabinose as sole carbon source.
WO 03/062430 and WO 06/009434 disclose yeast strains able to convert xylose into ethanol. These yeast strains are able to directly isomerise xylose into xylulose. WO 06/096130 discloses yeast strains able to convert xylose and arabinose simultaneously into ethanol.
Description of the invention Definitions Arabinose isomerase
The enzyme "arabinose isomerase" (EC 5.3.1.4) is herein defined as an enzyme that catalyses the direct isomerisation of L-arabinose into L-ribulose and vice versa. The enzyme is also known as a L-arabinose ketol-isomerase. Arabinose isomerases of the invention may be further defined by their amino acid sequence as herein described below. Likewise arabinose isomerases may be defined by the nucleotide sequences encoding the enzyme as well as by nucleotide sequences hybridising to a reference {araA) nucleotide sequence encoding a arabinose isomerase as herein described below.
L-ribulokinase The enzyme "L-ribulokinase" (EC 2.7.1.16) is herein defined as an enzyme that catalyses the reaction ATP + L-ribulose = ADP + L-ribulose 5 -phosphate. A ribulose kinase of the invention may be further defined by its amino acid sequence as herein described below. Likewise a ribulose kinase may be defined by the nucleotide sequences encoding the enzyme as well as by nucleotide sequences hybridising to a reference nucleotide sequence (araB) encoding a xylulose kinase as herein described below.
L-ribulose-5-phosphate 4-epimerase The enzyme "L-ribulose-5-phosphate 4-epimerase" (5.1.3.4) is herein defined as an enzyme that catalyses the epimerisation of L-ribulose 5-phosphate into D-xylulose 5-phosphate and vice versa. The enzyme is also known as L-ribulose phosphate 4- epimerase or ribulose phosphate 4-epimerase. A ribulose 5-phosphate 4-epimerase of the invention may be further defined by its amino acid sequence as herein described below. Likewise a ribulose 5-phosphate 4-epimerase may be defined by the nucleotide sequences encoding the enzyme as well as by nucleotide sequences hybridising to a reference nucleotide sequence (araD) encoding a ribulose 5-phosphate 4-epimerase as herein described below.
D-ribulose 5-phosphate 3-epimerase The enzyme "D-ribulose 5-phosphate 3-epimerase" (5.1.3.1) is herein defined as an enzyme that catalyses the epimerisation of D-xylulose 5-phosphate into D-ribulose 5-phosphate and vice versa. The enzyme is also known as phosphoribulose epimerase; erythrose-4-phosphate isomerase; phosphoketopentose 3-epimerase; xylulose phosphate 3-epimerase; phosphoketopentose epimerase; ribulose 5-phosphate 3- epimerase; D-ribulose phosphate-3-epimerase; D-ribulose 5-phosphate epimerase; D- ribulose-5-P 3-epimerase; D-xylulose-5-phosphate 3-epimerase; pentose-5-phosphate 3-epimerase; or D-ribulose-5 -phosphate 3-epimerase. Ribulose 5-phosphate isomerase
The enzyme "ribulose 5-phosphate isomerase" (EC 5.3.1.6) is herein defined as an enzyme that catalyses direct isomerisation of D-ribose 5-phosphate into D-ribulose 5-phosphate and vice versa. The enzyme is also known as phosphopentosisomerase; phosphoriboisomerase; ribose phosphate isomerase; 5-phosphoribose isomerase; D- ribose 5-phosphate isomerase; D-ribose-5 -phosphate ketol-isomerase; or D-ribose-5- phosphate aldose-ketose-isomerase. Transketolase
The enzyme "transketolase" (EC 2.2.1.1) is herein defined as an enzyme that catalyses the reaction: D-ribose 5-phosphate + D-xylulose 5-phosphate into sedoheptulose 7-phosphate + D-glyceraldehyde 3-phosphate and vice versa. The enzyme is also known as glycolaldehydetransferase or sedoheptulose-7-phosphate:D- glyceraldehyde- 3 -phosphate glycolaldehydetransferase. Transaldolase
The enzyme "transaldolase" (EC 2.2.1.2) is herein defined as an enzyme that catalyses the reaction: sedoheptulose 7-phosphate + D-glyceraldehyde 3-phosphate into D-erythrose 4-phosphate + D-fructose 6-phosphate and vice versa. The enzyme is also known as dihydroxyacetonetransferase; dihydroxyacetone synthase; formaldehyde transketolase; or sedoheptulose-7-phosphate:D-glyceraldehyde-3-phosphate glycerone- transferase. A transaldolase of the invention may be further defined by its amino acid sequence as herein described below. Aldose reductase
The enzyme "aldose reductase" (EC 1.1.1.21) is herein defined as any enzyme that is capable of reducing an aldose to the corresponding alditol and vice versa. In the context of the present invention an aldose reductase may be any unspecific aldose reductase that is native (endogenous) to a host cell of the invention and that is capable of reducing aldopentoses such as arabinose, xylose or xylulose to arabinitol or xylitol, respectively. Unspecific aldose reductases catalyse the reaction: aldose + NAD(P)H + H+ <→ alditol + NAD(P)+. The enzyme has a wide specificity and is also known as aldose reductase; polyol dehydrogenase (NADP+); alditol:NADP oxidoreductase; alditol:NADP+ 1 -oxidoreductase; NADPH-aldopentose reductase; or NADPH-aldose reductase. A particular example of such an unspecific aldose reductase that is endogenous to S. cerevisiae and that is encoded by the GRE3 gene (Traff et al., 2001, Appl. Environ. Microbiol. 67: 5668-74).
Xylose isomerase The enzyme "xylose isomerase" (EC 5.3.1.5) is herein defined as an enzyme that catalyses the direct isomerisation of D-xylose into D-xylulose and vice versa. The enzyme is also known as a D-xylose ketoisomerase. Some xylose isomerases are also capable of catalysing the conversion between D-glucose and D-fructose and are therefore sometimes referred to as glucose isomerase. Xylose isomerases require bivalent cations like magnesium or manganese as cofactor. Xylose isomerases of the invention may be further defined by their amino acid sequence as herein described below. Likewise xylose isomerases may be defined by the nucleotide sequences encoding the enzyme as well as by nucleotide sequences hybridising to a reference nucleotide sequence encoding a xylose isomerase as herein described below. A unit (U) of xylose isomerase activity is herein defined as the amount of enzyme producing 1 nmol of xylulose per minute, under conditions as described by Kuyper et al. (2003, FEMS Yeast Res. 4: 69-78). Xylulose kinase
The enzyme "xylulose kinase" (EC 2.7.1.17) is herein defined as an enzyme that catalyses the reaction ATP + D-xylulose = ADP + D-xylulose 5-phosphate. The enzyme is also known as a phosphorylating xylulokinase, D-xylulokinase or ATP:D- xylulose 5 -phosphotransferase. Sequence identity and similarity
Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. "Similarity" between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. "Identity" and "similarity" can be readily calculated by known methods. The terms "substantially identical", "substantial identity" or "essentially similar" or "essential similarity" means that two peptide or two nucleotide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default parameters, share at least a certain percentage of sequence identity as defined elsewhere herein. GAP uses the Needleman and Wunsch global alignment algorithm to align two sequences over their entire length, maximizing the number of matches and minimizes the number of gaps. Generally, the GAP default parameters are used, with a gap creation penalty = 50 (nucleotides) / 8 (proteins) and gap extension penalty = 3 (nucleotides) / 2 (proteins). For nucleotides the default scoring matrix used is nwsgapdna and for proteins the default scoring matrix is Blosum62 (Henikoff & Henikoff, 1992, PNAS 89, 915-919). It is clear than when RNA sequences are said to be essentially similar or have a certain degree of sequence identity with DNA sequences, thymine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence. Sequence alignments and scores for percentage sequence identity may be determined using computer programs, such as the GCG Wisconsin Package, Version 10.3, available from Accelrys Inc., 9685 Scranton Road, San Diego, CA 92121-3752 USA or the open-source software Emboss for Windows (current version 2.7.1-07). Alternatively percent similarity or identity may be determined by searching against databases such as FASTA, BLAST, etc. Optionally, in determining the degree of amino acid similarity, the skilled person may also take into account so-called "conservative" amino acid substitutions, as will be clear to the skilled person. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine- valine, and asparagine-glutamine. Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place. Preferably, the amino acid change is conservative. Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gin or his; Asp to glu; Cys to ser or ala; GIn to asn; GIu to asp; GIy to pro; His to asn or gin; He to leu or val; Leu to ile or val; Lys to arg; gin or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, Val to ile or leu. Hybridising nucleic acid sequences
Nucleotide sequences encoding the enzymes of the invention may also be defined by their capability to hybridise with the nucleotide sequences of SEQ ID NO.'s 10 - 18, respectively, under moderate, or preferably under stringent hybridisation conditions. Stringent hybridisation conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridise at a temperature of about 65°C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at 65°C in a solution comprising about 0.1 M salt, or less, preferably 0.2 x SSC or any other solution having a comparable ionic strength. Preferably, the hybridisation is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridisation of sequences having about 90% or more sequence identity.
Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least 50 nucleotides, preferably of about 200 or more nucleotides, to hybridise at a temperature of about 45°C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M salt, preferably 6 x
SSC or any other solution having a comparable ionic strength. Preferably, the hybridisation is performed overnight, i.e. at least for 10 hours, and preferably washing is performed for at least one hour with at least two changes of the washing solution.
These conditions will usually allow the specific hybridisation of sequences having up to 50% sequence identity. The person skilled in the art will be able to modify these hybridisation conditions in order to specifically identify sequences varying in identity between 50% and 90%.
Operably linked
As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame. Promoter
As used herein, the term "promoter" refers to a nucleic acid fragment that functions to control the transcription of one or more genes, located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. Protein
The terms "protein" or "polypeptide" are used interchangeably and refer to molecules consisting of a chain of amino acids, without reference to a specific mode of action, size, 3-dimensional structure or origin. Homologous The term "homologous" when used to indicate the relation between a given
(recombinant) nucleic acid or polypeptide molecule and a given host organism or host cell, is understood to mean that in nature the nucleic acid or polypeptide molecule is produced by a host cell or organisms of the same species, preferably of the same variety or strain. If homologous to a host cell, a nucleic acid sequence encoding a polypeptide will typically (but not necessarily) be operably linked to another (heterologous) promoter sequence and, if applicable, another (heterologous) secretory signal sequence and/or terminator sequence than in its natural environment. It is understood that the regulatory sequences, signal sequences, terminator sequences, etc. may also be homologous to the host cell. In this context, the use of only "homologous" sequence elements allows the construction of "self-cloned" genetically modified organisms (GMO's) (self-cloning is defined herein as in European Directive 98/81/EC Annex II). When used to indicate the relatedness of two nucleic acid sequences the term "homologous" means that one single- stranded nucleic acid sequence may hybridize to a complementary single- stranded nucleic acid sequence. The degree of hybridization may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as discussed later. Heterologous The term "heterologous" when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature. Heterologous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but has been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such nucleic acids encode proteins that are not normally produced by the cell in which the DNA is transcribed or expressed. Similarly exogenous RNA encodes for proteins not normally expressed in the cell in which the exogenous RNA is present. Heterologous nucleic acids and proteins may also be referred to as foreign nucleic acids or proteins. Any nucleic acid or protein that one of skill in the art would recognize as heterologous or foreign to the cell in which it is expressed is herein encompassed by the term heterologous nucleic acid or protein. The term heterologous also applies to non- natural combinations of nucleic acid or amino acid sequences, i.e. combinations where at least two of the combined sequences are foreign with respect to each other.
Detailed description of the invention In a first aspect the present invention relates to a eukaryotic cell comprising nucleotide sequences as defined in (a), (b) and (c), whereby the expression of the nucleotide sequences confers to the cell the ability to convert L-arabinose into D- xylulose 5-phosphate. Expressly included in the invention are eukaryotic cells that may already have the ability to convert L-arabinose into D-xylulose 5-phosphate (at a low level) and wherein expression of the nucleotide sequences as defined in (a), (b) and (c) increases the cell's ability to convert L-arabinose into D-xylulose 5-phosphate. Preferably, in the cells of the invention, the ability to convert L-arabinose into D- xylulose 5-phosphate is the ability to convert L-arabinose into D-xylulose 5-phosphate through the subsequent reactions of 1) isomerisation of arabinose into ribulose; 2) phosphorylation of ribulose to ribulose 5-phosphate; and, 3) epimerisation of ribulose 5-phosphate into D-xylulose 5-phosphate. Preferably expression of the nucleotide sequences confers to, or increases in the cell the ability to grow on arabinose as sole carbon and/or energy source, more preferably expression of the nucleotide sequences confers to the cell, or increases in the ability to grow on arabinose as sole carbon and/or energy source through conversion of arabinose into D-xylulose 5-phosphate (and further metabolism of D-xylulose 5-phosphate).
The nucleotide sequence (a) preferably is a nucleotide sequence encoding an arabinose isomerase, preferably a L-arabinose isomerase as herein defined above. The nucleotide sequence encoding the arabinose isomerase preferably is selected from the group consisting of:
(i) a nucleotide sequence encoding an arabinose isomerase comprising an amino acid sequence that has at least 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 1, 2 and 3;
(ii) a nucleotide sequence comprising a nucleotide sequence that has at least 70, 80,
90, 95, 98, 99 or 100% sequence identity with at least one of the nucleotide sequences of SEQ ID NO's: 10, 11 and 12;
(iii) a nucleotide sequence the complementary strand of which hybridises to a nucleotide sequence of (i) or (ii); and,
(iv) a nucleotide sequence the sequences of which differs from the sequence of a nucleotide sequence of (iii) due to the degeneracy of the genetic code.
The nucleotide sequence (b) preferably is a nucleotide sequence encoding a ribulokinase, preferably a L-ribulokinase as herein defined above. The nucleotide sequence encoding the ribulokinase preferably is selected from the group consisting of:
(i) a nucleotide sequence encoding a ribulokinase comprising an amino acid sequence that has at least 55, 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 4, 5 and 6;
(ii) a nucleotide sequence comprising a nucleotide sequence that has at least 65, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the nucleotide sequences of SEQ ID NO's: 13, 14 and 15;
(iii) a nucleotide sequence the complementary strand of which hybridises to a nucleotide sequence of (i) or (ii); and,
(iv) a nucleotide sequence the sequences of which differs from the sequence of a nucleotide sequence of (iii) due to the degeneracy of the genetic code.
The nucleotide sequence (c) preferably is a nucleotide sequence encoding a ribulose-5-P-4-epimerase, preferably a L-ribulose-5-P-4-epimerase as herein defined above. The nucleotide sequence encoding the ribulose-5-P-4-epimerase preferably is selected from the group consisting of: (i) a nucleotide sequence encoding a ribulose-5-P-4-epimerase comprising an amino acid sequence that has at least 55, 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 7, 8 and 9; (ii) a nucleotide sequence comprising a nucleotide sequence that has at least 65, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the nucleotide sequences of SEQ ID NO's: 16, 17 and 18;
(iii) a nucleotide sequence the complementary strand of which hybridises to a nucleotide sequence of (i) or (ii); and,
(iv) a nucleotide sequence the sequences of which differs from the sequence of a nucleotide sequence of (iii) due to the degeneracy of the genetic code.
A nucleotide sequence encoding an arabinose isomerase comprising an amino acid sequence that has at least 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 1, 2 and 3, preferably encodes an amino acid sequence wherein active site residues, and/or residues involved in metal ion- and/or substrate-binding are conserved. Such residues may be derived by comparison of the amino acid sequences of SEQ ID NO's: 1, 2 and 3 with the crystal structure of the E. coli L-arabinose isomerase (Manjasetty and Chance, 2006, J MoI Biol. 360(2):297-309). In addition more than 166 amino acid sequences of arabinose isomerases are known in the art. Sequence alignments of SEQ ID NO's: 1, 2 and 3 with these known arabinose isomerase amino acid sequences will indicate conserved regions and amino acid positions, the conservation of which are important for structure and enzymatic activity. These regions and positions will tolerate no or only conservative amino acid substitutions. Amino acid substitutions outside of these regions and positions are unlikely to greatly affect arabinose isomerase activity.
A nucleotide sequence encoding an L-ribulokinase comprising an amino acid sequence that has at least 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 4, 5 and 6, preferably encodes an amino acid sequence wherein active site residues, and/or residues involved in substrate -binding are conserved. Such residues may be derived by comparison of the amino acid sequences of SEQ ID NO's: 4, 5 and 6 with the crystal structure of the E. coli L-ribulokinase (Lee and Bendet, 1967, Biol Chem. 242(9):2043-50; Lee et al., 1970, J Biol Chem. 245(6): 1357-61). In addition more than 5000 amino acid sequences of ribulokinases are known in the art. Sequence alignments of SEQ ID NO's: 4, 5 and 6 with these known ribulokinase amino acid sequences will indicate conserved regions and amino acid positions, the conservation of which are important for structure and enzymatic activity. These regions and positions will tolerate no or only conservative amino acid substitutions. Amino acid substitutions outside of these regions and positions are unlikely to greatly affect ribulokinase activity.
A nucleotide sequence encoding a ribulose-5-P-4-epimerase comprising an amino acid sequence that has at least 60, 70, 80, 90, 95, 98, 99 or 100% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 7, 8 and 9, preferably encodes an amino acid sequence wherein active site residues, residues involved in metal ion- and substrate-binding and/or residues involved in intersubunit interface are conserved. Such residues may be derived by comparison of the amino acid sequences of SEQ ID NO's: 7, 8 and 9 with the crystal structure of the E. coli ribulose-5-P-4- epimerase (Luo et al., 2001, Biochemistry. 40(49): 14763-71) and comparisons with the structurally related aldolases (Kroemer and Schulz, 2002, Acta Crystallogr D Biol Crystallogr. 58(Pt 5):824-32; Joerger et al., 2000, Biochemistry. 39(20):6033-41). In addition more than 600 amino acid sequences of ribulose-5-P-4-epimerases and related aldolases are known in the art. Sequence alignments of SEQ ID NO's: 7, 8 and 9 with these known epimerase/aldolase amino acid sequences will indicate conserved regions and amino acid positions, the conservation of which are important for structure and enzymatic activity. These regions and positions will tolerate no or only conservative amino acid substitutions. Amino acid substitutions outside of these regions and positions are unlikely to greatly affect ribulose-5-P-4-epimerase activity. In accordance with the invention the eukaryotic host cell may comprise any possible combination of at least one nucleotide sequence as defined in (a), at least one nucleotide sequence as defined in (b) and at least one nucleotide sequence as defined in (c). Herein a nucleotide sequence as defined in (a) can be a nucleotide sequence with a percentage of sequence identity as indicated with an amino acid sequences of an arabinose isomerase (araA) of at least one of Clavibacter michiganensis (C), Arthrobacter aurescens (A) and Gramella forsetii (G); a nucleotide sequence as defined in (b) can be a nucleotide sequence with a percentage of sequence identity as indicated with an amino acid sequences of a L-ribulose kinase (araB) of at least one of Clavibacter michiganensis (C), Arthrobacter aurescens (A) and Gramella forsetii (G); and, a nucleotide sequence as defined in (c) can be a nucleotide sequence with a percentage of sequence identity as indicated with an amino acid sequences of an ribulose-5-P-4-epimerase (araD) of at least one of Clavibacter michiganensis (C), Arthrobacter aurescens (A) and Gramella forsetii (G). In particular the following combinations are included in the invention: AAA; AAC; AAG; ACA; ACC; ACG; AGA; AGC; AGG; CAA; CAC; CAG; CCA; CCC; CCG; CGA; CGC; CGG; GAA; GAC; GAG; GCA; GCC; GCG; GGA; GGC; GGG. Herein the first position in each triplet indicates the type of the araA sequence, the second position indicates the type of araB sequence, and the third position indicates the type of araD sequence, whereby the letters "C", "A" and "G" indicate amino acid sequences with a percentage amino acid identity as indicated to the corresponding enzymes of Clavibacter michiganensis (C), Arthrobacter aurescens (A) and Gramella forsetii (G), respectively.
In a preferred embodiment of the invention, at least one of the nucleotide sequences as defined in (a), (b) and (c) of claim 1 encodes an amino acid sequences that originate from a bacterial genus selected from the group consisting of Clavibacter, Arthrobacter and Gramella, i.e. the amino acid sequence is identical to an amino acid sequence as it naturally occurs in one of these genera. More preferably, at least one of the nucleotide sequences as defined in (a), (b) and (c) of claim 1 encodes an amino acid sequences that originate from a bacterial species selected from the group consisting of Clavibacter michiganensis, Arthrobacter aurescens and Gramella forsetii, i.e. the amino acid sequence is identical to an amino acid sequence as it naturally occurs in one of these species.
To increase the likelihood that the arabinose isomerase, the ribulokinase and the ribulose-5-P-4-epimerase are expressed at sufficient levels and in active form in the cells of the invention, the nucleotide sequence encoding these enzymes, as well as other enzymes of the invention (see below), are preferably adapted to optimise their codon usage to that of the host cell in question. The adaptiveness of a nucleotide sequence encoding an enzyme to the codon usage of a host cell may be expressed as codon adaptation index (CAI). The codon adaptation index is herein defined as a measurement of the relative adaptiveness of the codon usage of a gene towards the codon usage of highly expressed genes in a particular host cell or organism. The relative adaptiveness (w) of each codon is the ratio of the usage of each codon, to that of the most abundant codon for the same amino acid. The CAI index is defined as the geometric mean of these relative adaptiveness values. Non-synonymous codons and termination codons (dependent on genetic code) are excluded. CAI values range from 0 to 1, with higher values indicating a higher proportion of the most abundant codons (see Sharp and Li , 1987, Nucleic Acids Research 15: 1281-1295; also see: Jansen et al., 2003, Nucleic Acids Res. ^31_(8):2242-51). An adapted nucleotide sequence preferably has a CAI of at least 0.2, 0.3, 0.4, 0.5, 0.6 or 0.7. Most preferred are the sequences as listed in SEQ ID NO's: 10 - 18, which have been codon optimised for expression in S. cerevisiae cells.
The cell of the invention, preferably is a cell capable of active or passive pentose (arabinose and xylose) transport into the cell. The cell preferably contains active glycolysis. The cell further preferably contains an endogenous pentose phosphate pathway. The cell further preferably contains enzymes for conversion of arabinose (and xylose), optionally through pyruvate, to a desired fermentation product such as ethanol, lactic acid, 3 -hydroxy -propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3-propane-diol, ethylene, glycerol, β-lactam antibiotics and cephalosporins. A particularly preferred cell is a cell that is naturally capable of alcoholic fermentation, preferably, anaerobic alcoholic fermentation. The cell further preferably has a high tolerance to ethanol, a high tolerance to low pH (i.e. capable of growth at a pH lower than 5, 4, or 3) and towards organic acids like lactic acid, acetic acid or formic acid and sugar degradation products such as furfural and hydroxy- methylfurfural, and a high tolerance to elevated temperatures. Any of these characteristics or activities of the cell may be naturally present in the cell or may be introduced or modified by genetic modification, preferably by self cloning or by the methods of the invention described below. A suitable cell is a cultured cell, a cell that may be cultured in fermentation process e.g. in submerged or solid state fermentation. Particularly suitable cells are eukaryotic microorganism like e.g. fungi, however, most suitable for use in the present inventions are yeasts or filamentous fungi.
Yeasts are herein defined as eukaryotic microorganisms and include all species of the subdivision Eumycotina (Alexopoulos, C. J., 1962, In: Introductory Mycology, John Wiley & Sons, Inc., New York) that predominantly grow in unicellular form. Yeasts may either grow by budding of a unicellular thallus or may grow by fission of the organism. Preferred yeasts as host cells belong to the genera Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces, and Yarrowia. Preferably the yeast is capable of anaerobic fermentation, more preferably anaerobic alcoholic fermentation. Over the years suggestions have been made for the introduction of various organisms for the production of bio-ethanol from crop sugars. In practice, however, all major bio-ethanol production processes have continued to use the yeasts of the genus Saccharomyces as ethanol producer. This is due to the many attractive features of Saccharomyces species for industrial processes, i.e., a high acid-, ethanol- and osmo-tolerance, capability of anaerobic growth, and of course its high alcoholic fermentative capacity. Preferred yeast species as fungal host cells include S. cerevisiae, S. exiguus, S. bayanus, K. lactis, K. marxianus and Schizosaccharomyces pombe.
Filamentous fungi are herein defined as eukaryotic microorganisms that include all filamentous forms of the subdivision Eumycotina. These fungi are characterized by a vegetative mycelium composed of chitin, cellulose, and other complex polysaccharides. The filamentous fungi of the present invention are morphologically, physiologically, and genetically distinct from yeasts. Vegetative growth by filamentous fungi is by hyphal elongation and carbon catabolism of most filamentous fungi is obligately aerobic. Preferred filamentous fungi as host cells belong to the genera Aspergillus, Trichoderma, Humicola, Acremonium, Fusarium, and Penicillium.
In a cell of the invention, the nucleotide sequence as defined in (a), (b) and (c) are preferably operably linked to a promoter that causes sufficient expression of the nucleotide sequences in the cell to confer to the cell the ability to convert L-arabinose into D-xylulose 5 -phosphate. Preferably, each of the nucleotide sequence as defined in (a), (b) and (c) is operably linked to a promoter that causes sufficient expression of the nucleotide sequences in the cell to confer to the cell the ability to convert L-arabinose into D-xylulose 5-phosphate. More preferably the promoter(s) cause sufficient expression of the nucleotide sequences confers to the cell the ability to grow on arabinose as sole carbon and/or energy source, most preferably the promoter(s) cause sufficient expression of the nucleotide sequences confers to the cell the ability to grow on arabinose as sole carbon and/or energy source through conversion of arabinose into D-xylulose 5-phosphate (and further metabolism of D-xylulose 5-phosphate). Suitable promoters for expression of the nucleotide sequence as defined in (a), (b) and (c) include promoters that are insensitive to catabolite (glucose) repression and/or that do require xylose for induction. Promoters having these characteristics are widely available and known to the skilled person. Suitable examples of such promoters include e.g. promoters from glycolytic genes such as the phosphofructokinase (PPK), triose phosphate isomerase (TPI), glyceraldehyde- 3 -phosphate dehydrogenase (GPD, TDH3 or GAPDH), pyruvate kinase (PYK), phosphoglycerate kinase (PGK), glucose-6- phosphate isomerase promoter (PGIl) promoters from yeasts or filamentous fungi; more details about such promoters from yeast may be found in (WO 93/03159). Other useful promoters are ribosomal protein encoding gene promoters, the lactase gene promoter (LAC4), alcohol dehydrogenase promoters (ADHl, ADH4, and the like), the enolase promoter (ENO), the hexose(glucose) transporter promoter (HXT7), and the cytochrome cl promoter (CYCl). Other promoters, both constitutive and inducible, and enhancers or upstream activating sequences will be known to those of skill in the art. Preferably the promoter that is operably linked to nucleotide sequence as defined in (a), (b) and (c) is homologous to the host cell. It is preferred that for expression of each of the nucleotide sequence as defined in (a), (b) and (c) a different promoter is used. This will improved stability of the expression construct by avoiding homologous recombination between repeated promoter sequences and it avoids competition different copies of the promoter for limiting trans-acting factors.
A cell of the invention further preferably comprises a genetic modification that increases the flux of the pentose phosphate pathway as described in WO 06/009434. In particular, the genetic modification causes an increased flux of the non-oxidative part pentose phosphate pathway. A genetic modification that causes an increased flux of the non-oxidative part of the pentose phosphate pathway is herein understood to mean a modification that increases the flux by at least a factor 1.1, 1.2, 1.5, 2, 5, 10 or 20 as compared to the flux in a strain which is genetically identical except for the genetic modification causing the increased flux. The flux of the non-oxidative part of the pentose phosphate pathway may be measured as described in WO 06/009434.
Genetic modifications that increase the flux of the pentose phosphate pathway may be introduced in the cells of the invention in various ways. These including e.g. achieving higher steady state activity levels of xylulose kinase and/or one or more of the enzymes of the non-oxidative part pentose phosphate pathway and/or a reduced steady state level of unspecific aldose reductase activity. These changes in steady state activity levels may be effected by selection of mutants (spontaneous or induced by chemicals or radiation) and/or by recombinant DNA technology e.g. by overexpression or inactivation, respectively, of genes encoding the enzymes or factors regulating these genes.
In a preferred cell of the invention, the genetic modification comprises overexpression of at least one enzyme of the (non-oxidative part) pentose phosphate pathway. Preferably the enzyme is selected from the group consisting of the enzymes encoding for ribulose-5 -phosphate isomerase, ribulose-5 -phosphate 3-epimerase, transketolase and transaldolase. Various combinations of enzymes of the (non- oxidative part) pentose phosphate pathway may be overexpressed. E.g. the enzymes that are overexpressed may be at least the enzymes ribulose-5-phosphate isomerase and ribulose-5-phosphate 3-epimerase; or at least the enzymes ribulose-5-phosphate isomerase and transketolase; or at least the enzymes ribulose-5-phosphate isomerase and transaldolase; or at least the enzymes ribulose-5-phosphate 3-epimerase and transketolase; or at least the enzymes ribulose-5-phosphate 3-epimerase and transaldolase; or at least the enzymes transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate 3-epimerase, transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate isomerase, transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate isomerase, ribulose-5-phosphate 3-epimerase, and transaldolase; or at least the enzymes ribulose-5-phosphate isomerase, ribulose-5- phosphate 3-epimerase, and transketolase. In one embodiment of the invention each of the enzymes ribulose-5-phosphate isomerase, ribulose-5-phosphate 3-epimerase, transketolase and transaldolase are overexpressed in the cell of the invention. Preferred is a cell in which the genetic modification comprises at least overexpression of the enzyme transaldolase. More preferred is a cell in which the genetic modification comprises at least overexpression of both the enzymes transketolase and transaldolase as such a host cell is already capable of anaerobic growth on arabinose. In fact, under some conditions we have found that cells overexpressing only the transketolase and the transaldolase already have the same anaerobic growth rate on arabinose as do cells that overexpress all four of the enzymes, i.e. the ribulose-5-phosphate isomerase, ribulose- 5-phosphate 3-epimerase, transketolase and transaldolase. Moreover, cells of the invention overexpressing both of the enzymes ribulose-5-phosphate isomerase and ribulose-5-phosphate 3-epimerase are preferred over cells overexpressing only the isomerase or only the 3-epimerase as overexpression of only one of these enzymes may produce metabolic imbalances.
There are various means available in the art for overexpression of enzymes in the cells of the invention. In particular, an enzyme may be overexpressed by increasing the copynumber of the gene coding for the enzyme in the cell, e.g. by integrating additional copies of the gene in the cell's genome, by expressing the gene from an episomal multicopy expression vector or by introducing an episomal expression vector that comprises multiple copies of the gene. The coding sequence used for overexpression of the enzymes preferably is homologous to the host cell of the invention. However, coding sequences that are heterologous to the host cell of the invention may likewise be applied. Alternatively overexpression of enzymes in the cells of the invention may be achieved by using a promoter that is not native to the sequence coding for the enzyme to be overexpressed, i.e. a promoter that is heterologous to the coding sequence to which it is operably linked. Although the promoter preferably is heterologous to the coding sequence to which it is operably linked, it is also preferred that the promoter is homologous, i.e. endogenous to the cell of the invention. Preferably the heterologous promoter is capable of producing a higher steady state level of the transcript comprising the coding sequence (or is capable of producing more transcript molecules, i.e. mRNA molecules, per unit of time) than is the promoter that is native to the coding sequence, preferably under conditions where arabinose or arabinose and glucose are available as carbon sources, more preferably as major carbon sources (i.e. more than 50% of the available carbon source consists of arabinose or arabinose and glucose), most preferably as sole carbon sources. Suitable promoters in this context include promoters as described above for expression of the nucleotide sequences as defined in (a), (b) and
(C). A further preferred cell of the invention comprises a genetic modification that reduces unspecific aldose reductase activity in the cell. Preferably, unspecific aldose reductase activity is reduced in the host cell by one or more genetic modifications that reduce the expression of or inactivates a gene encoding an unspecific aldose reductase. Preferably, the genetic modifications reduce or inactivate the expression of each endogenous copy of a gene encoding an unspecific aldose reductase that is capable of reducing an aldopentose, including arabinose, xylose and xylulose, in the cell's genome. A given cell may comprise multiple copies of genes encoding unspecific aldose reductases as a result of di-, poly- or aneu-ploidy, and/or a cell may contain several different (iso)enzymes with aldose reductase activity that differ in amino acid sequence and that are each encoded by a different gene. Also in such instances preferably the expression of each gene that encodes an unspecific aldose reductase is reduced or inactivated. Preferably, the gene is inactivated by deletion of at least part of the gene or by disruption of the gene, whereby in this context the term gene also includes any non-coding sequence up- or down-stream of the coding sequence, the (partial) deletion or inactivation of which results in a reduction of expression of unspecific aldose reductase activity in the host cell. A nucleotide sequence encoding an aldose reductase whose activity is to be reduced in the cell of the invention and amino acid sequences of such aldose reductases are described in WO 06/009434 and include e.g. the (unspecific) aldose reductase genes of S. cerevisiae GRE3 gene (Traff et al., 2001, Appl. Environm. Microbiol. 67: 5668-5674) and orthologues thereof in other species.
In a further preferred embodiment, the cell of the invention that has the ability to convert L-arabinose into D-xylulose 5-phosphate expressing in addition has the ability of isomerising xylose to xylulose as e.g. described in WO 03/0624430 and in WO 06/009434. The ability of isomerising xylose to xylulose is preferably conferred to the cell by transformation with a nucleic acid construct comprising a nucleotide sequence encoding a xylose isomerase. Preferably the cell thus acquires the ability to directly isomerise xylose into xylulose. More preferably the cell thus acquires the ability to grow aerobically and/or anaerobically on xylose as sole energy and/or carbon source though direct isomerisation of xylose into xylulose (and further metabolism of xylulose). It is herein understood that the direct isomerisation of xylose into xylulose occurs in a single reaction catalysed by a xylose isomerase, as opposed to the two step conversion of xylose into xylulose via a xylitol intermediate as catalysed by xylose reductase and xylitol dehydrogenase, respectively.
Several xylose isomerases (and their amino acid and coding nucleotide sequences) that may be successfully used to confer to the cell of the invention the ability to directly isomerise xylose into xylulose have been described in the art. These include the xylose isomerase of Piromyces sp. and of other anaerobic fungi that belongs to the families Neocallimastix, Caecomyces, Piromyces, Orpinomyces, or Ruminomyces (WO 03/0624430), the xylose isomerase of the bacterial genus Bacteroides, including e.g. B. thetaiotaomicron (WO 06/009434) and B. fragilis, and the xylose isomerase of the anaerobic fungus Cyllamyces aberensis (US 20060234364). Preferably, a xylose isomerase that may be used to confer to the cell of the invention the ability to directly isomerise xylose into xylulose is a xylose isomerase comprising an amino acid sequence that has at least 70, 75, 80, 83% amino acid identity with the amino acid sequence of SEQ ID NO. 19 or 20. The cell of the invention that has the ability of isomerising xylose to xylulose further preferably comprises xylulose kinase activity so that xylulose isomerised from xylose may be metabolised to pyruvate. Preferably, the cell contains endogenous xylulose kinase activity. More preferably, a cell of the invention comprises a genetic modification that increases the specific xylulose kinase activity. Preferably the genetic modification causes overexpression of a xylulose kinase, e.g. by overexpression of a nucleotide sequence encoding a xylulose kinase. The gene encoding the xylulose kinase may be endogenous to the cell or may be a xylulose kinase that is heterologous to the cell. A nucleotide sequence that may be used for overexpression of xylulose kinase in the cells of the invention is e.g. the xylulose kinase gene from S. cerevisiae (XKSl) as described by Deng and Ho (1990, Appl. Biochem. Biotechnol. 24-25: 193-199). Another preferred xylulose kinase is a xylose kinase that is related to the xylulose kinase from Piromyces (xylB; see WO 03/0624430). This Piromyces xylulose kinase is actually more related to prokaryotic kinase than to all of the known eukaryotic kinases such as the yeast kinase. The eukaryotic xylulose kinases have been indicated as nonspecific sugar kinases, which have a broad substrate range that includes xylulose. In contrast, the prokaryotic xylulose kinases, to which the Piromyces kinase is most closely related, have been indicated to be more specific kinases for xylulose, i.e. having a narrower substrate range. In the cells of the invention, a xylulose kinase to be overexpressed is overexpressed by at least a factor 1.1, 1.2, 1.5, 2, 5, 10 or 20 as compared to a strain which is genetically identical except for the genetic modification causing the overexpression. It is to be understood that these levels of overexpression may apply to the steady state level of the enzyme's activity, the steady state level of the enzyme's protein as well as to the steady state level of the transcript coding for the enzyme.
The cells according to the invention may comprises further genetic modifications that result in one or more of the characteristics selected from the group consisting of (a) increased transport of arabinose and/or xylose into the cell; (b) decreased sensitivity to catabolite repression; (c) increased tolerance to ethanol, osmolarity or organic acids; and, (e) reduced production of by-products. By-products are understood to mean carbon-containing molecules other than the desired fermentation product and include e.g. arabinitol, xylitol, glycerol and/or acetic acid. Any genetic modification described herein may be introduced by classical mutagenesis and screening and/or selection for the desired mutant, or simply by screening and/or selection for the spontaneous mutants with the desired characteristics. Alternatively, the genetic modifications may consist of overexpression of endogenous genes and/or the inactivation of endogenous genes.
Genes the overexpression of which is desired for increased transport of arabinose and/or xylose into the cell are preferably chosen form genes encoding a hexose or pentose transporter. In S. cerevisiae these genes include HXTl, HXT2, HXT4, HXT5, HXT7 and GAL2, of which HXT7, HXT5 and GAL2 are most preferred (see Sedlack and Ho, Yeast 2004; 21: 671-684). Similarly orthologues of these genes in other species may be overexpressed. Other genes that may be overexpressed in the cells of the invention include genes coding for glycolytic enzymes and/or ethanologenic enzymes such as alcohol dehydrogenases.
Preferred endogenous genes for inactivation include hexose kinase genes e.g. the S. cerevisiae HXK2 gene (see Diderich et al., 2001, Appl. Environ. Microbiol. 67: 1587-1593); the S. cerevisiae MIGl or MIG2 genes; genes coding for enzymes involved in glycerol metabolism such as the S. cerevisiae glycerol-phosphate dehydrogenase 1 and/or 2 genes; or (hybridising) orthologues of these genes in other species.
Other preferred further modifications of host cells for xylose fermentation are described in van Maris et al. (2006, Antonie van Leeuwenhoek 90:391-418), WO2006/009434, WO2005/023998, WO2005/111214, and WO2005/091733.
Any of the genetic modifications of the cells of the invention as described herein are, in as far as possible, preferably introduced or modified by self cloning genetic modification. A preferred cell of the invention with one or more of the genetic modifications described above, including modifications obtained by selection of (spontaneous) mutants, has the ability to grow on L-arabinose and optionally xylose as carbon/energy source, preferably as sole carbon source, and preferably under anaerobic conditions. Preferably the cell produces essentially no arabinitol, e.g. the arabinitol produced is below the detection limit or e.g. less than 5, 2, 1, 0.5, or 0.3 % of the carbon consumed on a molar basis. Preferably, in case carbon/energy source also includes xylose, the cell produces essentially no xylitol, e.g. the xylitol produced is below the detection limit or e.g. less than 5, 2, 1, 0.5, or 0.3 % of the carbon consumed on a molar basis. A cell of the invention preferably has the ability to grow on L-arabinose as sole carbon/energy source at a rate of at least 0.01, 0.02, 0.05, 0.1, 0.2, 0,25 or 0,3 h"1 under aerobic conditions, or, more preferably, at a rate of at least 0.005, 0.01, 0.02, 0.05, 0.08, 0.1, 0.12, 0.15 or 0.2 h"1 under anaerobic conditions. A cell of the invention preferably has the ability to grow on a mixture of glucose and L-arabinose (in a 1: 1 weight ratio) as sole carbon/energy source at a rate of at least 0.01, 0.02, 0.05, 0.1, 0.2, 0,25 or 0,3 h"1 under aerobic conditions, or, more preferably, at a rate of at least 0.005, 0.01, 0.02, 0.05, 0.08, 0.1, 0.12, 0.15 or 0.2 h"1 under anaerobic conditions.
Preferably, a cell of the invention has a specific L-arabinose consumption rate of at least 346, 400, 600, 700, 800, 900 or 1000 mg h"1 (g dry weight)"1. Preferably, a cell of the invention has a yield of fermentation product (such as ethanol) on L-arabinose that is at least 20, 40, 50, 60, 80, 90, 95 or 98% of the cell's yield of fermentation product (such as ethanol) on glucose. More preferably, the modified host cell's yield of fermentation product (such as ethanol) on L-arabinose is equal to the host cell's yield of fermentation product (such as ethanol) on glucose. Likewise, the modified host cell's biomass yield on L-arabinose is preferably at least 55, 60, 70, 80, 85, 90, 95 or 98% of the host cell's biomass yield on glucose. More preferably, the modified host cell's biomass yield on L-arabinose is equal to the host cell's biomass yield on glucose. It is understood that in the comparison of yields on glucose and L-arabinose both yields are compared under aerobic conditions or both under anaerobic conditions.
In another aspect the invention relates to a eukaryotic cell comprising nucleotide sequences as encoding (a1) an arabinose isomerase, (b1) a xylulose kinase, and (c1) a ribulose-5-P-4-epimerase, whereby the expression of the nucleotide sequences confers to the cell the ability to convert L-arabinose into D-xylulose 5 -phosphate. In this embodiment the broad substrate specificity of xylulose kinases, in particular eukaryotic xylulose kinases, is exploited to phosphorylate ribulose (and optionally xylulose). Expressly included in also this embodiment of the invention are eukaryotic cells that may already have the ability to convert L-arabinose into D-xylulose 5-phosphate (at a low level) and wherein expression of the nucleotide sequences as defined in (a1), (b1) and (c1) increases the cell's ability to convert L-arabinose into D-xylulose 5-phosphate. Preferably, in the cells of the invention, the ability to convert L-arabinose into D- xylulose 5-phosphate is the ability to convert L-arabinose into D-xylulose 5-phosphate through the subsequent reactions of 1) isomerisation of arabinose into ribulose; 2) phosphorylation of ribulose to ribulose 5-phosphate; and, 3) epimerisation of ribulose 5-phosphate into D-xylulose 5-phosphate. Preferably expression of the nucleotide sequences confers to, or increases in the cell the ability to grow on arabinose as sole carbon and/or energy source, more preferably expression of the nucleotide sequences confers to the cell, or increases in the ability to grow on arabinose as sole carbon and/or energy source through conversion of arabinose into D-xylulose 5-phosphate (and further metabolism of D-xylulose 5-phosphate).
The nucleotide sequence (a1) encoding the arabinose isomerase may be a nucleotide sequence (a) as defined above, however the nucleotide sequence may also encode any other, preferably bacterial, arabinose isomerase, e.g. those from E. coli, Bacillus and Lactobacillus as described in e.g. EP 1499708 and Wisselink et al. (2007, supra). Preferably, the nucleotide sequence encoding the arabinose isomerase comprises an amino acid sequence that has at least 30, 35, 40, 45, or 50% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 1, 2 and 3. The nucleotide sequence (b1) encoding a polypeptide with xylulose kinase activity preferably comprises an amino acid sequence having at least 50, 60, 70, 80, 90 or 95% identity with SEQ ID NO. 21.
The nucleotide sequence (c1) encoding the ribulose-5-P-4-epimerase may be a nucleotide sequence (c) as defined above, however the nucleotide sequence may also encode any other, preferably bacterial, ribulose-5-P-4-epimerase, e.g. those from E. coli, Bacillus and Lactobacillus as described in e.g. EP 1499708 and Wisselink et al. (2007, supra). Preferably, the nucleotide sequence encoding the ribulose-5-P-4- epimerase comprises an amino acid sequence that has at least 30, 35, 40, 45, or 50% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 7, 8 and 9.
The eukaryotic cell comprising the nucleotide sequence encoding an eukaryotic xylulose kinase, in stead of a bacterial ribulose kinase, may the same as the above described cells comprising the nucleotide sequence encoding a bacterial ribulose kinase sequences in all aspects except for the more broadly defined nucleotide sequences (a1) and (c1) and the different nucleotide sequence (b1).
In another aspect the invention relates to a process for producing a fermentation product selected from the group consisting of ethanol, lactic acid, 3 -hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3-propane-diol, ethylene, glycerol, β-lactam antibiotics and cephalosporins. The process preferably comprises the steps of: a) fermenting a medium containing a source of arabinose, and optionally xylose, with a cell as defined hereinabove, whereby the cell ferments arabinose, and optionally xylose, to the fermentation product, and optionally, b) recovery of the fermentation product.
In addition to a source of arabinose the carbon source in the fermentation medium may also comprise a source of glucose. The skilled person will further appreciate that the fermentation medium may further also comprise other types of carbohydrates such as e.g. in particular a source of xylose. The sources of arabinose, glucose and xylose may be arabinose, glucose and xylose as such (i.e. as monomelic sugars) or they may be in the form of any carbohydrate oligo- or polymer comprising arabinose, glucose and/or xylose units, such as e.g. lignocellulose, arabinans, xylans, cellulose, starch and the like. For release of arabinose, glucose and/or xylose units from such carbohydrates, appropriate carbohydrases (such as arabinases, xylanases, glucanases, amylases, cellulases, glucanases and the like) may be added to the fermentation medium or may be produced by the modified host cell. In the latter case the modified host cell may be genetically engineered to produce and excrete such carbohydrases. An additional advantage of using oligo- or polymeric sources of glucose is that it enables to maintain a low(er) concentration of free glucose during the fermentation, e.g. by using rate- limiting amounts of the carbohydrases preferably during the fermentation. This, in turn, will prevent repression of systems required for metabolism and transport of non- glucose sugars such as arabinose and xylose. In a preferred process the modified host cell ferments both the arabinose and glucose, and optionally xylose, preferably simultaneously in which case preferably a modified host cell is used which is insensitive to glucose repression to prevent diauxic growth. In addition to a source of arabinose (and glucose) as carbon source, the fermentation medium will further comprise the appropriate ingredient required for growth of the modified host cell. Compositions of fermentation media for growth of eukaryotic microorganisms such as yeasts and filamentous fungi are well known in the art. The fermentation process may be an aerobic or an anaerobic fermentation process. An anaerobic fermentation process is herein defined as a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than 5, 2.5 or 1 mmol/L/h, more preferably 0 mmol/L/h is consumed (i.e. oxygen consumption is not detectable), and wherein organic molecules serve as both electron donor and electron acceptors. In the absence of oxygen, NADH produced in glycolysis and biomass formation, cannot be oxidised by oxidative phosphorylation. To solve this problem many microorganisms use pyruvate or one of its derivatives as an electron and hydrogen acceptor thereby regenerating NAD+. Thus, in a preferred anaerobic fermentation process pyruvate is used as an electron (and hydrogen acceptor) and is reduced to fermentation products such as ethanol, lactic acid, 3-hydroxy- propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3- propane-diol, ethylene, glycerol, β-lactam antibiotics and cephalosporins. Anaerobic processes of the invention are preferred over aerobic processes because anaerobic processes do not require investments and energy for aeration and in addition, anaerobic processes produce higher product yields than aerobic processes. Alternatively, the fermentation process of the invention may be run under aerobic oxygen-limited conditions. Preferably, in an aerobic process under oxygen-limited conditions, the rate of oxygen consumption is at least 5.5, more preferably at least 6 and even more preferably at least 7 mmol/L/h.
The fermentation process is preferably run at a temperature that is optimal for the modified cells of the invention. Thus, for most yeasts or fungal cells, the fermentation process is performed at a temperature which is less than 42°C, preferably less than 38°C. For yeast or filamentous fungal cells, the fermentation process is preferably performed at a temperature which is lower than 35, 33, 30 or 28°C and at a temperature which is higher than 20, 22, or 25°C.
Preferably in the fermentation processes of the invention, the cells stably maintain the nucleic acid constructs that confer to the cell the ability of converting arabinose into D-xylulose 5 -phosphate, and optionally isomerising xylose to xylulose. Preferably in the process at least 10, 20, 50 or 75% of the cells retain the abilities to convert arabinose into D-xylulose 5-phosphate, and optionally isomerise xylose to xylulose after 50 generations of growth, preferably under industrial fermentation conditions. A preferred fermentation process according to the invention is a process for the production of ethanol, whereby the process comprises the steps of: a) fermenting a medium containing a source of arabinose, and optionally xylose, with a cell as defined hereinabove, whereby the cell ferments arabinose, and optionally xylose, to ethanol, and optionally, b) recovery of the ethanol. The fermentation medium may further be performed as described above. In the process the volumetric ethanol productivity is preferably at least 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0 or 10.0 g ethanol per litre per hour. The ethanol yield on arabinose and/or glucose and/or xylose in the process preferably is at least 50, 60, 70, 80, 90, 95 or 98%. The ethanol yield is herein defined as a percentage of the theoretical maximum yield, which, for arabinose, glucose and xylose is 0.51 g. ethanol per g. arabinose, glucose or xylose.
A further preferred fermentation process according to the invention is a process which comprises fermenting a medium containing a source of arabinose and a source of xylose wherein however two separate strains of cells are used, a first strain of cells as defined hereinabove except that cells of the first strain do not have the ability to (directly) isomerise xylose into xylulose, which cells of the first strain ferment arabinose to the fermentation product; and a second strain of cells as defined hereinabove except that cells of the second strain do not have the ability to convert arabinose to xylulose 5 -phosphate, which cells of the second strain ferment xylose to the fermentation product. The process optionally comprises the step of recovery of the fermentation product. The cells of the first and second are further as otherwise described hereinabove.
In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one". All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Description of the figures Figure 1
Physical map of plasmid pRS316 GGA showing the three ara genes The most important restriction-enzyme recognition sites used for cloning are indicated.
Figure 2
Colony PCR on RN1002 and as a negative control on the host strain RNlOOO. The Fermentas lkb ladder is used to control the length of the amplified fragments. On the left side RN1002 and on the right side RNlOOO results are shown. All fragment sizes are as expected. Used primers are indicated in Table 1.
Examples 1. Example 1 1.1. Plasmids
1.1.1 araA For high level of expression of the bacterial araA and araD genes the corresponding expression cassettes are inserted into the 2μ plasmid pAKX002 that already comprises the Piromyces xylA gene linked the S. cerevisiae TPI promoter. The araA expression cassettes is constructed by amplifying the S. cerevisiae TDH3 promoter (Pmm) with oligo's that allow to link the TDH3 promoter to the 5' end of the synthetic araA coding sequences of Arthrobacter aurescens (SEQ ID NO. 10), Clavibacter michiganensis (SEQ ID NO. 11) and Gramella forsetii (SEQ ID NO. 12), and amplifying the S. cerevisiae ADHl terminator with oligo's that allow to link the 3' end of the synthetic araA coding sequences to the ADHl terminator (TADHI)- The two fragments are extracted from gel and mixed in roughly equimolar amounts with the fragments of the synthetic araA coding sequences. On this mixture a PCR is performed using the 5' PTDH3 oligo and the 3' TADHI oligo. The resulting VTDH3-araA-T ADHI cassette is gel purified, cut at the 5 'and 3' restriction sites and then ligated into pAKX002, resulting in plasmids pRN-AAaraA, pRN-CMaraA and pRN-GFaraA, respectively.
1.1.2 araD The three araD constructs are made by first amplifying a truncated version of the S. cerevisiae HXT7 promoter (?HXT7) with oligo's that allow to link the HXT7 promoter to the 5' end of the synthetic araD coding sequences of Arthrobacter aurescens (SEQ ID NO. 16), Clavibacter michiganensis (SEQ ID NO. 17) and Gramella forsetii (SEQ ID NO. 18), and amplifying the PGIl terminator with oligo's that allow to link the 3' end of the synthetic araD coding sequences to the PGIl terminator region (TVG/). The resulting fragments were extracted from gel and mixed in roughly equimolar amounts with the synthetic araD coding sequences, after which a PCR was performed using the 5' PfflT7 oligo and the 3' T^G/ oligo. The resulting Vjixπ-araD-TpGii cassettes are gel purified, cut at the 5 'and 3' restriction sites and ligated into pRN-AAaraA, pRN- CMaraA and pRN-GFaraA, respectively, resulting in plasmids pRN-AAaraAD, pRN- CMaraAD and pRN-GFaraAD, respectively. 1.1.3 araB
For the expression of the three bacterial araB genes, the integrational plasmid pRS305 is used (Gietz and Sugino, 1988, Gene 74:527-534). Aside from the bacterial AraB genes, the S.cerevisiae XKSl gene was also included on this vector. For this, the VADHI- XKSl -T cYci containing Pvul fragment from p415 ADHXKS was ligated into the Pvul digested vector backbone from the integration plasmid pRS305, resulting in pRN- XKSl. For expression of the bacterial araB genes, three cassettes containing the synthetic araB coding sequences of Arthrobacter aurescens (SEQ ID NO. 13), Clavibacter michiganensis (SEQ ID NO. 14) and Gramella forsetii (SEQ ID NO. 15) genes between the PGIl promoter (Ppβi) and ADHl terminator (TADHI) is constructed by PCR amplification. The AraB expression cassettes are made by amplifying the PGIl promoter with oligonucleotides that allow to link the PGIl promoter to the 5' end of the synthetic araB coding sequences, and amplifying the ADHl terminator with oligo's that allow to link the 3' end of the synthetic araB coding sequences to the ADHl terminator (TADHI)- The resulting Ppcπ-araB-TADHi cassettes are gel purified, digested at the 5'and 3' restriction sites and are then ligated into pRN-XKSl, to yield plasmids pRN-XKSl- AAaraB, pRN-XKSl-CMaraB and pRN-XKSl-GFaraB, respectively. 1.2 Strains Media for cultivations of Saccharomyces cerevisiae strains, shake flask and fermenter cultivations as well as sequential batch fermentation under aerobic, oxygen-limited and anaerobic conditions were performed as described in Wisselink et al. (2007, AEM Accepts, published online ahead of print on 1 June 2007; Appl. Environ. Microbiol, doi: 10.1128/AEM.00177-07). 1.2.1 Derivation of host strain RN679 from RWB218 The S. cerevisiae strains in this work are derived from the xylose-fermenting strain RWB217 (Kuyper et al., 2005a, FEMS Yeast Res. 5:399-409): RWB217 has the following genotype: MATA ura3-52 Ieu2-112 loxP-PTPI::(-266,-l)TALl gre3::hphMX pUGPTPI-TKLl pUGPTPI-RPEl KanloxP-PTPI: :(-?,- I)RKIl {p415ADHXKS, pAKX002}. Strain RWB218 is obtained by selection of RWB217 for improved growth on D-xylose (Kuyper et al., 2005b, FEMS Yeast Res. 5:925-934) by plating and restreaking on MYD plates. RWB218 is grown non- selectively on YPD in order to facilitate the loss of plasmids pAKX002 and p415ADHXKSl (Kuyper et al., 2005a, supra), harbouring the URA3 and LEU2 selective markers, respectively. RWB218 is plated on YPD, single colonies are screened for plasmid loss by testing for uracil and leucine auxotrophy. In order to remove a KanMX cassette - still present after integrating the RKIl overexpression construct (Kuyper et al., 2005a, supra) - a strain from which both plasmids are lost is transformed with pSH47, containing the ere recombinase (Guldener et al., 1996, Nucleic Acids Res., 24:2519-252410). Transformants containing pSH47 are resuspended in YP with 1% D-galactose and incubated for 1 hour at 300C. Cells are plated on YPD and colonies are screened for loss of the KanMX marker (G418 resistance) and pSH47 (URA3). A strain that has lost both the KanMX marker and the pSH47 plasmid is designated as RN679. The genotype of RN679 is: MATA ura3-52 Ieu2-112 loxP-PTPI::(-266,-l)TALl gre3::hphMX pUGPTPI-TKLl pUGPTPI-RPEl KanloxP-PTPI::(-?,-l)RKIl.
1.2.2 Transformations of RN679 RN679 is transformed with:
1) pRN-AAaraAD and pRN-XKSl-AAaraB, resulting in strain RN680; 2) pRN-CMaraAD and pRN-XKSl-CMaraB, resulting in strain RN681; and 3) pRN-GFaraAD and pRN-XKSl-GFaraB, resulting in strain RN681.
1.2.3 Selection of strains RN680, RN681 and RN682 for aerobic growth on L- arabinose
Strains RN680, RN681 and RN682 do not grow on solid synthetic medium supplemented with 2% (w/v) L-arabinose (MYA). Therefore, evolutionary engineering is applied for the selection of cells of the strains RN680, RN681 and RN682 with an improved specific growth rate on arabinose. Prior to the selection in synthetic medium supplemented with 2% of arabinose, cells are pre-grown in synthetic medium with galactose, as it is known that galactose-induced S. cerevisiae cells can transport L- arabinose via the galactose permease GAL2p (Kou et al., 1970, J. Bacterid. 103:671- 67817). Galactose-grown cells of strains RN680, RN681, RN682 and control strain RWB218 are transferred to shake flasks containing MY supplemented with 0.1% D- galactose and 2% L-arabinose. After approximately several weeks of cultivation in the single initial shake flask, the cultures of strains RN680, RN681, RN682 IMSOOOl show very slow growth after depletion of the galactose, in contrast to the reference strain RWB218 which does not grow after depletion of galactose. Cells of the cultures are next transferred to fresh synthetic medium supplied with 2% of L-arabinose (MYA). After again 1-3 weeks of cultivation in MYA descendants of strains RN680, RN681, RN682 grow with an improved doubling time, whereas strain RWB219 still does not grow. Next cells are sequentially transferred each time an OD660 of 2-3 is reached to fresh MYA with a start OD660 of approximately 0.05 and gradually the specific growth rate of the sequentially transferred cultures increases. 1.2.4 Selection of strains RN680, RN681 and RN682 for anaerobic growth on L- arabinose
To allow for a more gradual transfer to anaerobic conditions, the aerobically evolved strains, as obtained in Example 2.3 above, are first grown under oxygen-limited conditions. As soon as growth is observed under oxygen-limited conditions, the culture is switched to anaerobic conditions in the next batch cycle. Upon arabinose depletion, as indicated by the CO2 percentage dropping below 0.05% after the CO2 production peak, a new cycle is initiated by either manual or automated replacement of approximately 90% of the culture with fresh synthetic medium containing 20 g I"1 L- arabinose. In 10-15 cycles, the anaerobic specific growth rate increases as estimated from the CO2 profile. After 20-25 cycles no significant further increase of the growth rate is noticed. Single colonies are isolated on solid MYA for anaerobically evolved descendants of each of RN680, RN681 and RN682.
Example 2 2.1 Donor organisms and genes
As described in Example 1, three donor organisms were selected:
• Arthrobacter aurescens (A)
• Clavibacter michiganensis (C)
• Gramella forsetii (G) The arabinose genes selected were:
• araA: arabinose isomerase EC 3.5.1.4
• araB: ribulokinase EC 2.7.1.16
• araD: L-ribulose-5-phosphate 4-epimerase EC 5.1.3.4
The 9 genes were synthesized by EXONBIO based on sequences that were optimized for codon usage in yeast by Nextgen Sciences. See sequence listings.
To express the araA gene in Saccharomyces cerevisiae the HXT7 promoter (410bp) and the PGIl terminator (329bp) sequences were used. To express the araB gene in Saccharomyces cerevisiae the TPIl promoter (899bp) and the ADHl terminator (351bp) sequences were used.
To express the araD gene in Saccharomyces cerevisiae the TDH3 promoter (686bp) and the CYCl terminator (288bp) sequences were used The first three nucleotides in front of the ATG were modified into AAA in order to optimize expression.
2.2 Host organism
The yeast host strain was RNlOOO. This strain is a derivative of strain RWB 218 (Kuyper et al., FEMS Yeast Research 5, 2005, 399-409). The plasmid pAKX002 encoding the Piromyces XyIA is lost in RNlOOO. The genotype of the host strain is: MatA, ura3-52, Ieu2-112, gre3::hphMX, loxP-Ptpi::TALl, KanloxP-Ptpi::RKIl, pUGPtpi-TKLl, pUGPtpi-RPEl,{p415 PadhlXKSlTcycl-LEU2J
2.3 Molecular techniques employed in plasmid construction
The synthetic genes were amplified using the 'polymerase chain reaction (PCR) 'technique facilitating cloning. For each reaction two short synthetic oligomers 'primers' were used. The one in the 'forward' and the other in the 'reverse' mode. Constitutive promoter sequences and terminator sequences from Saccharomyces cerevisiae were also amplified using PCR. In Table 1 an overview of all primers used in this study is given. To minimize PCR-induced sequence mistakes, the Finnzymes proofreading enzyme Phusion was used.
The plasmid used to express the ara genes into yeast is pRS316 (Sikorski R.S., Hieter P., "A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae" Genetics 122:19-27(1989), accession U03442, ATCC77145). This plasmid is a centromeric plasmid (low copynumber in yeast) that has the URA3 gene for selection.
The construction of the pRS316 GGA plasmid is given below. The primers used contained specific restriction-enzyme recognition sites. Construction involved standard molecular biological techniques. GaraA: promoter cut with Notl and Pstl; ORF cut with Pstl and Xhol; terminator cut with Xhol and 55/WI.
GaraB: promoter cut with Agel and Xbal; ORF cut with Xbal and BssHll; terminator cut with BssHII and 55/WI. 3X3YYOYYYXYYOYOXXXXYYYOYOXYYYY3XYXY3Y33X3W .HY.H0
OOXYXOSYYXSOYOXXOSYYYXYSXOOOYOYOOXSXX HYW3
3Y33Y3XYY3Y33Y0XYYYY3XYXY3Y30X3YY .HYWS
3XXX0YX33Y33Y33Y3YYYX3330Y0Y03X3XX HYYY
33Y33YX33Y3XY333XYYYY3XYXY3Y30X3YY ^YYY
33YY3Y3XY3XX3Y3YYYXXXX33YX33XX33YYXX HXY
33YXYXYXWYXX3X333XYYY3YOYO3X3XY3YYY ^XY
'l
Figure imgf000034_0001
The expression constructs were first assembled per gene and than ligated together into the plasmid pRS316 cut with Notl and Xhol. A and B in opposite direction (adjacent terminator sequences), B and D in opposite direction (adjacent promoter sequences). A physical map of the final plasmid p RS316 GGA is shown in Figure 1 and its sequence is depicted in SEQ ID NO: 22. Other combinations of AraA, AraB and AraD including the respective promoters were obtained as well and corresponding plasmids were constructed.
2.4 Transformation of the host organism and selection of transformants RNlOOO was transformed with plasmids using the 'Gietz method' (Gietz et al., 1992, Nucleic Acids Res. 1992 Mar 25;20(6):1425.). Primary selection of transformants was done on mineral medium (YNB+2% glucose) via uracil complementation. Further selection for transformants containing plasmid pRS316 GGA was done on YNB + 2% L-arabinose. Colonies emerging on plates of the latter medium grew slowly. However, via Colony PCR it was demonstrated that all three ara genes are present in the transformants (Figure 2). The yeast transformant thus obtained was designated Royal Nedalco collection number RN 1002 and harbours a plasmid with an expression construct for the expression of araA, araB and araD genes.
2.5 Oxic growth of the engineered Saccharomyces cerevisiae strain RN1002 at the expense of L-arabinose
The purpose of the experiment reported here was to demonstrate that strain RN 1002 has the ability to grow at the expense of L-arabinose under oxic (aerobic) conditions.
2.5.1 Media
Yeast nitrogen base (YNB, Difco) buffered with 0.17M KH2PO4 and 0.72M K2HPO4 at pH 5,5 was used for assessing oxic growth at the expense of arabinose. Incubation were performed in the presence of galactose in order to stimulate cell biomass production. After heat sterilization of the medium for 20 min at 120 0C, the sugars galactose (0.05%) and/or L-arabinose (1%) were added after filter sterilization.
2.5.2 Oxic cultivation 25 ml YNB with 0,5 g/1 galactose with or without 10 g/1 L-arabinose was inoculated with material derived from a single colony grown on solid medium (YNB agar with 1% L-arabinose and 0,05 % galactose). A culture without any sugar added served as an additional blank. The OD of this culture was below detection level. Cultures where incubated while shaking at 300C with oxygen from the air allowed to enter into the liquid medium. The concentrations of L-arabinose and galactose were determined at various times. Cell growth was monitored by measuring the OD.
2.5.3 Measurement of the optical densities Optical densities were analyzed by an (Perkin Elmer lambda 2S) spectrophotometer at 700 nm.
2.5.4 Determination of monomeric sugars
Sugar concentrations in filtered supernatants were determined by high-performance anion-exchange. It was performed on a Dionex system equipped with a CarboPac PA-I column (4 mm ID x 250 mm) in combination with a CarboPac PA guard column (4 mm x 50 mm). For the analysis of both L-arabinose and galactose, an isocratic elution (1 ml/min) of 25 minutes was carried out with water. Each elution was followed by a washing and equilibration step. Detection of the compounds was accomplished by the post-column addition of NaOH to the column eluent to raise the pH (>12) before it entered the PAD (Electrochemical detector ED40, Dionex).
2.5.5 Results
The results obtained are summarized in Table 2, which demonstrates that strain RN1002 has the ability to metabolize L-arabinose as witnessed by the consumption of L-arabinose and to grow at its expense as demonstrated by the increase in time of OD values of the L-arabinose-containing culture.
2.6 Anoxic production of ethanol at the expense of L-arabinose by the engineered Saccharomyces cerevisiae strain RN1002
The purpose of the experiment reported here was to demonstrate that strain RN 1002 has the ability to produce ethanol from L-arabinose under anoxic (anaerobic) conditions.
2.6.1 Media
For assessing anoxic ethanol production from L-arabinose, a medium containing yeast extract (1% w/w) and peptone (2% w/w) was used. After heat sterilization of the medium for 20 min at 120 0C, the sugars galactose(0.5%) and/or arabinose(2%) were added separately after heat sterilization at 110 0C.
2.6.2 Anoxic cultivation
To prepare a preculture, strain RN1002 was grown at 32 0C and pH5 in a shake flask culture on 100 ml medium containing yeast extract with peptone and with addition of the sugars galactose (0.5%) and arabinose (2%). After 70 h incubation, this culture was centrifuged twice and cells were resuspended to an OD of 112. This suspension was used to inoculate four anoxic operated stirred fermenters (BAM fermenters purchased from Halotec) with 1 ml each. The subsequent batch fermentations were performed at 32 0C and the working volumes of the four fermentations used in this study were 150 ml each.
2.6.3 Gas analysis
The exhaust gas was cooled by a condenser connected to a cryostat set at 4°C. The exhaust gas flow rate was measured with a Brooks Smart mass flow meter, which is calibrated for CO2 flow. This mass flow meter was located in a valve box interface (Halotec). The valve box contains all the mechanical parts of the system and its purpose is to control the gas flow of each flask and to house the sensors.
2.6.4 Measurement of the optical densities
Optical densities were analyzed by an (Perkin Elmer lambda 2S) spectrophotometer at 700 nm.
2.6.5 Determination of ethanol concentration
Ethanol concentrations in filtered supernatants were determined by HPLC analysis with a Bio-rad Aminex HPX-87H column at 65°C. The column was eluted with 0.25 M sulfuric acid at a flow rate of 0.55 ml min"1. 2.6.6 Determination of monomeric sugars
Sugar concentrations in filtered supernatants were determined by high-performance anion-exchange. It was performed on a Dionex system equipped with a CarboPac PA-I column (4 mm ID x 250 mm) in combination with a CarboPac PA guard column (4 mm x 50 mm). For the analysis of both L-arabinose and galactose, an isocratic elution (1 ml/min) of 25 minutes was carried out with water. Each elution was followed by a washing and equilibration step. Detection of the compounds was accomplished by the post-column addition of NaOH to the column eluent to raise the pH (>12) before it entered the PAD (Electrochemical detector ED40, Dionex). 2.6.7 Results The results obtained are summarized in Table 3 and demonstrate that strain RN1002 has the ability to convert L-arabinose into ethanol. Table 2 Time course of the optical density (A700) and cumulative L-arabinose and galactose consumption of strain RN1002 during oxic incubations.
Figure imgf000038_0001
Table 3 Time course of the optical density (A700) and cumulative L-arabinose and galactose consumption of strain RN1002 during anoxic incubations as well as the production of ethanol.
Figure imgf000039_0001

Claims

Claims
1. A eukaryotic cell comprising nucleotide sequences as defined in (a), (b) and (c), whereby the expression of the nucleotide sequences confers to, or increases in the cell the ability to convert L-arabinose into D-xylulose 5 -phosphate, wherein the nucleotide sequences (a), (b) and (c) are:
(a) a nucleotide sequence encoding an arabinose isomerase, wherein the nucleotide sequence selected from the group consisting of:
(i) a nucleotide sequence encoding an arabinose isomerase comprising an amino acid sequence that has at least 60% sequence identity with at least one of the amino acid sequences of SEQ ID NO' s: 1, 2 and 3;
(ii) a nucleotide sequence comprising a nucleotide sequence that has at least 70% sequence identity with at least one of the nucleotide sequences of SEQ ID NO's: 10, 11 and 12; (iii) a nucleotide sequence the complementary strand of which hybridises to a nucleotide sequence of (i) or (ii); and,
(iv) a nucleotide sequence the sequences of which differs from the sequence of a nucleotide sequence of (iii) due to the degeneracy of the genetic code,
(b) a nucleotide sequence encoding a ribulokinase, wherein the nucleotide sequence is selected from the group consisting of:
(i) a nucleotide sequence encoding a ribulokinase comprising an amino acid sequence that has at least 55% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 4, 5 and 6;
(ii) a nucleotide sequence comprising a nucleotide sequence that has at least 65% sequence identity with at least one of the nucleotide sequences of SEQ ID NO's: 13, 14 and 15;
(iii) a nucleotide sequence the complementary strand of which hybridises to a nucleotide sequence of (i) or (ii); and,
(iv) a nucleotide sequence the sequences of which differs from the sequence of a nucleotide sequence of (iii) due to the degeneracy of the genetic code; and,
(c) a nucleotide sequence encoding a ribulose-5-P-4-epimerase, wherein the nucleotide sequence is selected from the group consisting of: (i) a nucleotide sequence encoding a ribulose-5-P-4-epimerase comprising an amino acid sequence that has at least 55% sequence identity with at least one of the amino acid sequences of SEQ ID NO's: 7, 8 and 9;
(ii) a nucleotide sequence comprising a nucleotide sequence that has at least 65% sequence identity with at least one of the nucleotide sequences of SEQ ID NO's: 16, 17 and 18;
(iii) a nucleotide sequence the complementary strand of which hybridises to a nucleotide sequence of (i) or (ii); and,
(iv) a nucleotide sequence the sequences of which differs from the sequence of a nucleotide sequence of (iii) due to the degeneracy of the genetic code.
2. A cell according to claim 1, wherein at least one of the nucleotide sequences as defined in (a), (b) and (c) of claim 1 encodes an amino acid sequence that originate from a bacterial genus selected from the group consisting of Clavibacter, Arthrobacter and Gramella.
3. A cell according to claim 1 or 2, wherein the nucleotide sequence as defined in (a), (b) and (c) of claim 1 encode amino acid sequences that originate from a bacterial genus selected from the group consisting of Clavibacter michiganensis, Arthrobacter aurescens and Gramella forsetii.
4. A cell according to any one of the preceding claims, wherein the cell is a yeast or a filamentous fungus of a genus selected from the group consisting of Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces, Yarrowia, Aspergillus, Trichoderma, Humicola, Acremonium, Fusarium, and Penicillium.
5. A cell according to claim 4, wherein the cell is a yeast is capable of anaerobic alcoholic fermentation.
6. A cell according to claim 5, wherein the yeast belongs to a species selected from the group consisting of S. cerevisiae, S. exiguus, S. bayanus, K. lactis, K. marxianus and Schizosaccharomyces pombe.
7. A cell according to any one of the preceding claims, wherein the nucleotide sequence as defined in (a), (b) and (c) of claim 1 are operably linked to a promoter that causes sufficient expression of the nucleotide sequences in the cell to confer to the cell the ability to convert L-arabinose into D-xylulose 5 -phosphate.
8. A cell according to any one the preceding claims, wherein the cell comprises a genetic modification that increases the flux of the pentose phosphate pathway.
9. A cell according to claim 8, wherein by the genetic modification comprises overexpression of at least one gene of the non-oxidative part pentose phosphate pathway.
10. A cell according to claim 9, wherein the genetic modification comprises overexpression of at least the gene coding for a transaldolase.
11. A cell according to claim 10, wherein the genetic modification comprises overexpression of at least the genes coding for a transketolase and a transaldolase.
12. A cell according to claim 11, wherein the genetic modification comprises overexpression of all four genes encoding a D-ribulose 5-phosphate 3-epimerase, a ribulose 5-phosphate isomerase, a transketolase and a transaldolase.
13. The cell according to any one the preceding claims, whereby the host cell comprises a genetic modification that reduces unspecific aldose reductase activity in the cell.
14. The cell according to claim 13, whereby the genetic modification reduces the expression of, or inactivates a gene encoding an unspecific aldose reductase.
15. The cell according to claim 14, whereby the gene is inactivated by deletion of at least part of the gene or by disruption of the gene.
16. The cell according to any one of claims 13 - 15, whereby the expression of each gene in the cell that encodes an unspecific aldose reductase that is capable of reducing an aldopentose is reduced or inactivated.
17. A cell according to any one the preceding claims, wherein the cell exhibits the ability to directly isomerise xylose into xylulose.
18. A cell according to claim 17, whereby the cell further comprises a genetic modification that increases the specific xylulose kinase activity.
19. A cell according to claim 18, whereby the genetic modification comprises overexpression of a gene encoding a xylulose kinase.
20. A cell according to claim 18 or 19, whereby the xylulose kinase gene that is overexpressed is endogenous to the cell.
21. A cell according to any one of claims 1 - 7, wherein the cell comprises at least one further genetic modification that result in a characteristic selected from the group consisting of: (a) increase transport of at least one of xylose and arabinose into the host cell;
(b) decreased sensitivity to catabolite repression;
(c) increased tolerance to ethanol, osmolarity or organic acids; and,
(d) reduced production of by-products.
22. A cell according to any one of the preceding claims, whereby the cell expresses one or more enzymes that confer to the host cell the ability to produce at least one fermentation product selected from the group consisting of ethanol, lactic acid, 3- hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3-propane-diol, ethylene, glycerol, β-lactam antibiotics and cephalosporins.
23. A eukaryotic cell comprising nucleotide sequences as defined in (a'), (b1) and (c1), whereby the expression of the nucleotide sequences confers to, or increases in the cell the ability to convert L-arabinose into D-xylulose 5 -phosphate, wherein the nucleotide sequences (a'), (b1) and (c1) are: (a') a nucleotide sequence encoding an arabinose isomerase; (b1) a nucleotide sequence encoding a xylulose kinases; and, (c1) a nucleotide sequence encoding a ribulose-5-P-4-epimerase.
24. A process for producing a fermentation product selected from the group consisting of ethanol, lactic acid, 3 -hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3-propane-diol, ethylene, glycerol, β-lactam antibiotics and cephalosporins, whereby the process comprises the steps of:
(a) fermenting a medium containing a source of arabinose with cell as defined in any one of claims 1 - 23, whereby the host cell ferments arabinose to the fermentation product, and optionally,
(b) recovery of the fermentation product.
25. A process for producing a fermentation product selected from the group consisting of ethanol, lactic acid, 3 -hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, amino acids, 1,3-propane-diol, ethylene, glycerol, β-lactam antibiotics and cephalosporins, whereby the process comprises the steps of: (a) fermenting a medium containing at least one of a source of xylose and a source of arabinose with a cell as defined in any one of claims 17 - 23, whereby the cell ferments at least one of xylose and arabinose to the fermentation product, and optionally, (b) recovery of the fermentation product.
26. A process according to claim 24 or 25, whereby the medium also contains a source of glucose.
27. The process according to any one of claim 24 - 26, wherein the fermentation product is ethanol.
28. The process according to claim 27, whereby the volumetric ethanol productivity is at least 0.5 g ethanol per litre per hour.
29. The process according to claim 27 or 28, whereby the ethanol yield is at least 50 %.
30. The process according to any one of claims 24 to 29, wherein the process is anaerobic.
PCT/NL2008/050500 2007-07-19 2008-07-21 Novel arabinose-fermenting eukaryotic cells WO2009011591A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2693365A CA2693365A1 (en) 2007-07-19 2008-07-21 Novel arabinose-fermenting eukaryotic cells
EP08779046A EP2171038A2 (en) 2007-07-19 2008-07-21 Novel arabinose-fermenting eukaryotic cells
US12/669,688 US20100304454A1 (en) 2007-07-19 2008-07-21 Novel arabinose-fermenting eukaryotic cells
US14/623,811 US20150184203A1 (en) 2007-07-19 2015-02-17 Novel arabinose-fermenting eukaryotic cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92995107P 2007-07-19 2007-07-19
US60/929,951 2007-07-19
EP07112791 2007-07-19
EP07112791.4 2007-07-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/669,688 A-371-Of-International US20100304454A1 (en) 2007-07-19 2008-07-21 Novel arabinose-fermenting eukaryotic cells
US14/623,811 Division US20150184203A1 (en) 2007-07-19 2015-02-17 Novel arabinose-fermenting eukaryotic cells

Publications (2)

Publication Number Publication Date
WO2009011591A2 true WO2009011591A2 (en) 2009-01-22
WO2009011591A3 WO2009011591A3 (en) 2009-04-30

Family

ID=38551333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2008/050500 WO2009011591A2 (en) 2007-07-19 2008-07-21 Novel arabinose-fermenting eukaryotic cells

Country Status (4)

Country Link
US (2) US20100304454A1 (en)
EP (1) EP2171038A2 (en)
CA (1) CA2693365A1 (en)
WO (1) WO2009011591A2 (en)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003893A1 (en) 2009-07-10 2011-01-13 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
WO2011131667A1 (en) 2010-04-21 2011-10-27 Dsm Ip Assets B.V. Cell suitable for fermentation of a mixed sugar composition
WO2011149353A1 (en) 2010-05-27 2011-12-01 C5 Yeast Company B.V. Yeast strains engineered to produce ethanol from acetic acid and glycerol
WO2012049173A1 (en) 2010-10-13 2012-04-19 Dsm Ip Assets B.V. Polypeptides with permease activity
WO2012067510A1 (en) 2010-11-18 2012-05-24 C5 Yeast Company B.V. Yeast strains engineered to produce ethanol from glycerol
WO2012125027A1 (en) 2011-03-14 2012-09-20 Dsm Ip Assets B.V. Yeast strains that ferment uronic acids
EP2546336A1 (en) 2011-07-11 2013-01-16 DSM IP Assets B.V. Yeast strains that consume uronic acids and produce fermentation products such as ethanol
WO2013081456A2 (en) 2011-11-30 2013-06-06 Dsm Ip Assets B.V. Yeast strains engineered to produce ethanol from acetic acid and glycerol
EP2661987A1 (en) 2012-05-07 2013-11-13 Fabrice Delin Seat mounting
WO2014033019A1 (en) 2012-08-28 2014-03-06 Dsm Ip Assets B.V. Yeast strains engineered to produce ethanol from acetate
WO2014033018A1 (en) 2012-08-28 2014-03-06 Dsm Ip Assets B.V. Yeast strains engineered to produce ethanol from acetate
WO2014060377A1 (en) 2012-10-16 2014-04-24 Dsm Ip Assets B.V. Cells with improved pentose conversion
WO2014072232A1 (en) 2012-11-07 2014-05-15 Dsm Ip Assets B.V. pH CONTROLLED YEAST PROPAGATION
US20140141473A1 (en) * 2011-04-22 2014-05-22 Dsm Ip Assets B.V. Yeast cell capable of converting sugars including arabinose and xlose
WO2015028582A2 (en) 2013-08-29 2015-03-05 Dsm Ip Assets B.V. Glycerol and acetic acid converting yeast cells with improved acetic acid conversion
WO2015160257A1 (en) 2014-04-18 2015-10-22 Moralco B.V. Use of acetaldehyde in the fermentative production of ethanol
US9181563B2 (en) 2011-04-11 2015-11-10 Cargill, Incorporated Compositions and methods for increased ethanol production from biomass
WO2016012429A1 (en) 2014-07-24 2016-01-28 Dsm Ip Assets B.V. Yeast cell with improved pentose transport
WO2016120298A1 (en) 2015-01-28 2016-08-04 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2016120296A1 (en) 2015-01-28 2016-08-04 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2016120297A1 (en) 2015-01-28 2016-08-04 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2016131788A1 (en) * 2015-02-16 2016-08-25 Deinove L-arabinose assimilation pathway and uses thereof
WO2016169893A1 (en) 2015-04-20 2016-10-27 Dsm Ip Assets B.V. Whole fermentation broth
WO2016169892A1 (en) 2015-04-20 2016-10-27 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2016207144A1 (en) 2015-06-22 2016-12-29 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2017211957A1 (en) 2016-06-09 2017-12-14 Dsm Ip Assets B.V. Seed train for large scale enzyme production
WO2018019948A1 (en) 2016-07-29 2018-02-01 Dsm Ip Assets B.V. Polypeptides having cellulolytic enhancing activity and uses thereof
WO2018096019A1 (en) 2016-11-24 2018-05-31 Dsm Ip Assets B.V. Enzyme composition
WO2018096017A1 (en) 2016-11-24 2018-05-31 Dsm Ip Assets B.V. Enzyme composition
WO2018185071A1 (en) 2017-04-03 2018-10-11 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2019072732A1 (en) 2017-10-09 2019-04-18 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2019086369A1 (en) 2017-10-30 2019-05-09 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2019086370A1 (en) 2017-10-30 2019-05-09 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2019096718A1 (en) 2017-11-14 2019-05-23 Dsm Ip Assets B.V. Polypeptides with improved arabinose transport specificity
WO2019185681A1 (en) 2018-03-28 2019-10-03 Dsm Ip Assets B.V. Enzyme composition
WO2019185680A1 (en) 2018-03-28 2019-10-03 Dsm Ip Assets B.V. Enzyme composition
WO2019219804A1 (en) 2018-05-17 2019-11-21 Dsm Ip Assets B.V. Process for producing a polypeptide
WO2019229108A1 (en) 2018-05-30 2019-12-05 Dsm Ip Assets B.V. Process for producing sugars from carbohydrate materials
WO2020058253A1 (en) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of carbohydrate material and fermentation of sugars
WO2020058248A1 (en) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of carbohydrate material and fermentation of sugars
WO2020058249A1 (en) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of carbohydrate material and fermentation of sugars
WO2020182843A1 (en) 2019-03-12 2020-09-17 Dsm Ip Assets B.V. Process for producing a fermentation broth
US10844363B2 (en) 2015-08-05 2020-11-24 Cargill, Incorporated Xylose isomerase-modified yeast strains and methods for bioproduct production
WO2021048164A1 (en) 2019-09-10 2021-03-18 Dsm Ip Assets B.V. Enzyme composition
WO2021089877A1 (en) 2019-11-08 2021-05-14 Dsm Ip Assets B.V. Process for producing ethanol
WO2021119304A1 (en) 2019-12-10 2021-06-17 Novozymes A/S Microorganism for improved pentose fermentation
WO2022214460A1 (en) 2021-04-08 2022-10-13 Dsm Ip Assets B.V. Process for the preparation of a sugar product and a fermentation product
WO2022214458A1 (en) 2021-04-06 2022-10-13 Dsm Ip Assets B.V. Enzyme composition
WO2022214459A1 (en) 2021-04-06 2022-10-13 Dsm Ip Assets B.V. Enzyme composition
WO2022214457A1 (en) 2021-04-06 2022-10-13 Dsm Ip Assets B.V. Enzyme composition
WO2022261003A1 (en) 2021-06-07 2022-12-15 Novozymes A/S Engineered microorganism for improved ethanol fermentation

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192958A1 (en) 2011-02-28 2013-09-30 Midori Renewables Inc Polymeric acid catalysts and uses thereof
WO2013071112A1 (en) 2011-11-10 2013-05-16 Mascoma Corporation A genetically modified strain of s. cerevisiae engineered to ferment xylose and arabinose
WO2013163230A2 (en) * 2012-04-24 2013-10-31 Midori Renewables, Inc. Bio-based polymers and methods of producing thereof
US9238845B2 (en) 2012-08-24 2016-01-19 Midori Usa, Inc. Methods of producing sugars from biomass feedstocks
US9951326B2 (en) 2015-07-13 2018-04-24 MARA Renewables Corporation Enhancing microbial metabolism of C5 organic carbon
BR112018068981A2 (en) 2016-03-18 2019-04-16 Lallemand Hungary Liquidity Management Llc ras / camp / pka signaling route adjustment in yeast
JP2020099308A (en) * 2018-12-25 2020-07-02 トヨタ自動車株式会社 Recombinant yeast and method for producing ethanol using the same
CN113430186B (en) * 2021-04-15 2022-11-08 北京中医药大学深圳医院(龙岗)(深圳市龙岗区中医院) Fructokinase from fungus traditional Chinese medicine and coding gene and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062430A1 (en) * 2002-01-23 2003-07-31 Royal Nedalco B.V. Fermentation of pentose sugars
WO2003095627A1 (en) * 2002-05-08 2003-11-20 Forskarpatent I Syd Ab A modified yeast consuming l-arabinose
WO2006009434A1 (en) * 2004-07-16 2006-01-26 Technische Universiteit Delft Metabolic engineering of xylose fermenting eukaryotic cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1863901A1 (en) * 2005-03-11 2007-12-12 Forskarpatent i Syd AB Arabinose- and xylose-fermenting saccharomyces cerevisiae strains

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062430A1 (en) * 2002-01-23 2003-07-31 Royal Nedalco B.V. Fermentation of pentose sugars
WO2003095627A1 (en) * 2002-05-08 2003-11-20 Forskarpatent I Syd Ab A modified yeast consuming l-arabinose
WO2006009434A1 (en) * 2004-07-16 2006-01-26 Technische Universiteit Delft Metabolic engineering of xylose fermenting eukaryotic cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [Online] 6 February 2007 (2007-02-06), "L-arabinose isomerase (EC 5.3.1.4)." XP002454730 retrieved from EBI accession no. UNIPROT:A1RAY5 Database accession no. A1RAY5 *
DATABASE UniProt [Online] 6 February 2007 (2007-02-06), "L-ribulokinase (EC 2.7.1.16)." XP002454731 retrieved from EBI accession no. UNIPROT:A1RAY3 Database accession no. A1RAY3 *
DATABASE UniProt [Online] 6 February 2007 (2007-02-06), "L-ribulose-5-phosphate 4-epimerase (EC 5.1.3.4)." XP002454732 retrieved from EBI accession no. UNIPROT:A1RAY4 Database accession no. A1RAY4 *
MONGODIN EMMANUEL F ET AL: "Secrets of soil survival revealed by the genome sequence of Arthrobacter aurescens TC1" PLOS GENETICS, vol. 2, no. 12, December 2006 (2006-12), pages 2094-2106, XP002454726 ISSN: 1553-7390(print) 1553-7404(ele *
WISSELINK H WOUTER ET AL: "Engineering of Saccharomyces cerevisiae for efficient anaerobic alcoholic fermentation of L-arabinose" APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 73, no. 15, June 2007 (2007-06), pages 4881-4891, XP009090726 ISSN: 0099-2240 *

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10982235B2 (en) 2009-07-10 2021-04-20 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
CN112029804A (en) * 2009-07-10 2020-12-04 帝斯曼知识产权资产管理有限公司 Fermentative production of ethanol from glucose, galactose and arabinose using a recombinant yeast strain
AU2010270301A1 (en) * 2009-07-10 2012-02-02 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
WO2011003893A1 (en) 2009-07-10 2011-01-13 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
CN107058404A (en) * 2009-07-10 2017-08-18 帝斯曼知识产权资产管理有限公司 Using restructuring yeast strains from glucose, galactolipin and arabinose fermentative production of ethanol
US11649471B2 (en) 2009-07-10 2023-05-16 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
US10260075B2 (en) 2009-07-10 2019-04-16 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
CN102482688A (en) * 2009-07-10 2012-05-30 帝斯曼知识产权资产管理有限公司 Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
CN110257441A (en) * 2009-07-10 2019-09-20 帝斯曼知识产权资产管理有限公司 Using restructuring yeast strains from glucose, galactolipin and arabinose fermentative production of ethanol
AU2010270301A8 (en) * 2009-07-10 2014-03-20 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
JP2012532591A (en) * 2009-07-10 2012-12-20 ディーエスエム アイピー アセッツ ビー．ブイ． Fermentative production of ethanol from glucose, galactose, and arabinose using recombinant yeast strains
EP2451962B1 (en) 2009-07-10 2021-10-13 DSM IP Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
US9551015B2 (en) 2009-07-10 2017-01-24 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
EP3808851A1 (en) * 2009-07-10 2021-04-21 DSM IP Assets B.V. Process for galactose fermentation
AU2010270301B2 (en) * 2009-07-10 2015-03-19 Dsm Ip Assets B.V. Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
WO2011131667A1 (en) 2010-04-21 2011-10-27 Dsm Ip Assets B.V. Cell suitable for fermentation of a mixed sugar composition
WO2011149353A1 (en) 2010-05-27 2011-12-01 C5 Yeast Company B.V. Yeast strains engineered to produce ethanol from acetic acid and glycerol
AU2011315569C1 (en) * 2010-10-13 2016-02-04 Dsm Ip Assets B.V. Pentose and glucose fermenting yeast cell
US9353376B2 (en) 2010-10-13 2016-05-31 Dsm Ip Assets, B.V. Pentose and glucose fermenting yeast cell
WO2012049173A1 (en) 2010-10-13 2012-04-19 Dsm Ip Assets B.V. Polypeptides with permease activity
WO2012049179A2 (en) 2010-10-13 2012-04-19 Dsm Ip Assets B.V. Polypeptides with kinase activity
CN103154234B (en) * 2010-10-13 2016-08-17 帝斯曼知识产权资产管理有限公司 Ferment pentoses and the yeast cells of glucose
US9034608B2 (en) 2010-10-13 2015-05-19 Dsm Ip Assets, B.V. Polypeptides with permease activity
AU2011315569B2 (en) * 2010-10-13 2015-09-24 Dsm Ip Assets B.V. Pentose and glucose fermenting yeast cell
CN103154234A (en) * 2010-10-13 2013-06-12 帝斯曼知识产权资产管理有限公司 Pentose and glucose fermenting yeast cell
WO2012049170A3 (en) * 2010-10-13 2012-06-14 Dsm Ip Assets B.V. Pentose and glucose fermenting yeast cell
WO2012067510A1 (en) 2010-11-18 2012-05-24 C5 Yeast Company B.V. Yeast strains engineered to produce ethanol from glycerol
WO2012125027A1 (en) 2011-03-14 2012-09-20 Dsm Ip Assets B.V. Yeast strains that ferment uronic acids
US9181563B2 (en) 2011-04-11 2015-11-10 Cargill, Incorporated Compositions and methods for increased ethanol production from biomass
US9862975B2 (en) 2011-04-11 2018-01-09 Cargill, Incorporated Compositions and methods for increased ethanol production from biomass
US20140141473A1 (en) * 2011-04-22 2014-05-22 Dsm Ip Assets B.V. Yeast cell capable of converting sugars including arabinose and xlose
EP2546336A1 (en) 2011-07-11 2013-01-16 DSM IP Assets B.V. Yeast strains that consume uronic acids and produce fermentation products such as ethanol
WO2013081456A2 (en) 2011-11-30 2013-06-06 Dsm Ip Assets B.V. Yeast strains engineered to produce ethanol from acetic acid and glycerol
EP3321368A2 (en) 2011-11-30 2018-05-16 DSM IP Assets B.V. Yeast strains engineered to produce ethanol from acetic acid and glycerol
EP2661987A1 (en) 2012-05-07 2013-11-13 Fabrice Delin Seat mounting
WO2014033018A1 (en) 2012-08-28 2014-03-06 Dsm Ip Assets B.V. Yeast strains engineered to produce ethanol from acetate
WO2014033019A1 (en) 2012-08-28 2014-03-06 Dsm Ip Assets B.V. Yeast strains engineered to produce ethanol from acetate
WO2014060377A1 (en) 2012-10-16 2014-04-24 Dsm Ip Assets B.V. Cells with improved pentose conversion
EP3492579A1 (en) 2012-10-16 2019-06-05 DSM IP Assets B.V. Cells with improved pentose conversion
WO2014072232A1 (en) 2012-11-07 2014-05-15 Dsm Ip Assets B.V. pH CONTROLLED YEAST PROPAGATION
WO2015028582A2 (en) 2013-08-29 2015-03-05 Dsm Ip Assets B.V. Glycerol and acetic acid converting yeast cells with improved acetic acid conversion
WO2015160257A1 (en) 2014-04-18 2015-10-22 Moralco B.V. Use of acetaldehyde in the fermentative production of ethanol
WO2016012429A1 (en) 2014-07-24 2016-01-28 Dsm Ip Assets B.V. Yeast cell with improved pentose transport
WO2016120297A1 (en) 2015-01-28 2016-08-04 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2016120298A1 (en) 2015-01-28 2016-08-04 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2016120296A1 (en) 2015-01-28 2016-08-04 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
EP3640336A1 (en) 2015-01-28 2020-04-22 DSM IP Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
US10392623B2 (en) 2015-02-16 2019-08-27 Deinove L-arabinose assimilation pathway and uses thereof
WO2016131788A1 (en) * 2015-02-16 2016-08-25 Deinove L-arabinose assimilation pathway and uses thereof
WO2016169893A1 (en) 2015-04-20 2016-10-27 Dsm Ip Assets B.V. Whole fermentation broth
WO2016169892A1 (en) 2015-04-20 2016-10-27 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2016207144A1 (en) 2015-06-22 2016-12-29 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
US10844363B2 (en) 2015-08-05 2020-11-24 Cargill, Incorporated Xylose isomerase-modified yeast strains and methods for bioproduct production
WO2017211957A1 (en) 2016-06-09 2017-12-14 Dsm Ip Assets B.V. Seed train for large scale enzyme production
WO2018019948A1 (en) 2016-07-29 2018-02-01 Dsm Ip Assets B.V. Polypeptides having cellulolytic enhancing activity and uses thereof
WO2018096017A1 (en) 2016-11-24 2018-05-31 Dsm Ip Assets B.V. Enzyme composition
WO2018096019A1 (en) 2016-11-24 2018-05-31 Dsm Ip Assets B.V. Enzyme composition
WO2018185071A1 (en) 2017-04-03 2018-10-11 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2019072732A1 (en) 2017-10-09 2019-04-18 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2019086369A1 (en) 2017-10-30 2019-05-09 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2019086370A1 (en) 2017-10-30 2019-05-09 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
WO2019096718A1 (en) 2017-11-14 2019-05-23 Dsm Ip Assets B.V. Polypeptides with improved arabinose transport specificity
WO2019185681A1 (en) 2018-03-28 2019-10-03 Dsm Ip Assets B.V. Enzyme composition
WO2019185680A1 (en) 2018-03-28 2019-10-03 Dsm Ip Assets B.V. Enzyme composition
WO2019219804A1 (en) 2018-05-17 2019-11-21 Dsm Ip Assets B.V. Process for producing a polypeptide
WO2019229108A1 (en) 2018-05-30 2019-12-05 Dsm Ip Assets B.V. Process for producing sugars from carbohydrate materials
WO2020058249A1 (en) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of carbohydrate material and fermentation of sugars
WO2020058253A1 (en) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of carbohydrate material and fermentation of sugars
WO2020058248A1 (en) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of carbohydrate material and fermentation of sugars
WO2020182843A1 (en) 2019-03-12 2020-09-17 Dsm Ip Assets B.V. Process for producing a fermentation broth
WO2021048164A1 (en) 2019-09-10 2021-03-18 Dsm Ip Assets B.V. Enzyme composition
WO2021089877A1 (en) 2019-11-08 2021-05-14 Dsm Ip Assets B.V. Process for producing ethanol
WO2021119304A1 (en) 2019-12-10 2021-06-17 Novozymes A/S Microorganism for improved pentose fermentation
WO2022214458A1 (en) 2021-04-06 2022-10-13 Dsm Ip Assets B.V. Enzyme composition
WO2022214459A1 (en) 2021-04-06 2022-10-13 Dsm Ip Assets B.V. Enzyme composition
WO2022214457A1 (en) 2021-04-06 2022-10-13 Dsm Ip Assets B.V. Enzyme composition
WO2022214460A1 (en) 2021-04-08 2022-10-13 Dsm Ip Assets B.V. Process for the preparation of a sugar product and a fermentation product
WO2022261003A1 (en) 2021-06-07 2022-12-15 Novozymes A/S Engineered microorganism for improved ethanol fermentation

Also Published As

Publication number Publication date
CA2693365A1 (en) 2009-01-22
US20100304454A1 (en) 2010-12-02
US20150184203A1 (en) 2015-07-02
WO2009011591A3 (en) 2009-04-30
EP2171038A2 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
US20150184203A1 (en) Novel arabinose-fermenting eukaryotic cells
US10093914B2 (en) Xylose isomerase genes and their use in fermentation of pentose sugars
CA2664646C (en) Metabolic engineering of arabinose- fermenting yeast cells
EP1468093B1 (en) Fermentation of pentose sugars
EP2663645B1 (en) Yeast strains engineered to produce ethanol from glycerol
WO2009109633A1 (en) A pentose sugar fermenting cell
EP2250263A1 (en) A pentose sugar fermenting cell
WO2009109630A1 (en) A pentose sugar fermenting cell
WO2014033019A1 (en) Yeast strains engineered to produce ethanol from acetate
DK2069476T3 (en) Metabolic MODIFICATION of arabinose-fermenting YEAST CELLS
WO2014033018A1 (en) Yeast strains engineered to produce ethanol from acetate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08779046

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2008779046

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008779046

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2693365

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12669688

Country of ref document: US